

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## **SAFE, a new therapeutic intervention for families of children with autism: study protocol for a feasibility randomised controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025006
Article Type:	Protocol
Date Submitted by the Author:	25-Jun-2018
Complete List of Authors:	McKenzie, Rebecca; University of Plymouth, Institute of Education Dallos, Rudi; Department of Clinical Psychology, University of Plymouth Hancocks, Helen Ewings, Paul; Research Design Service, Research Office Barton, Andy; South West Research Design Service Vassallo, Tara Myhill, Craig
Keywords:	autism, family therapy, intervention, feasibility

SCHOLARONE™  
Manuscripts

1  
2  
3 **SAFE, a new therapeutic intervention for families of children with autism:**  
4 **study protocol for a feasibility randomised controlled trial**  
5  
6  
7

8 Rebecca McKenzie<sup>1</sup>, Rudi Dallos<sup>1</sup>, Helen Hancocks<sup>2</sup>, Paul Ewings<sup>3</sup>, Andy Barton<sup>3</sup>, Tara  
9 Vassallo<sup>1</sup>, Craig Myhill<sup>1</sup>  
10  
11  
12  
13  
14  
15

16 Author affiliations  
17

- 18 1. Plymouth University. Plymouth UK
- 19 2. Peninsular Clinical Trials Unit. Plymouth UK
- 20 3. Regional Design Service. South West. UK

21 Correspondence to: Dr Rebecca McKenzie [rebecca.mckenzie@plymouth.ac.uk](mailto:rebecca.mckenzie@plymouth.ac.uk)  
22  
23  
24  
25

26 Key words: Family Therapy, autism, intervention, feasibility, mental health  
27  
28  
29  
30  
31  
32

33 Word count: 4267 excluding title page, abstract and references  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Incidence of autistic traits, mental health problems, stress and poor coping skills is high among family members of children with autism. These problems are coupled with maladaptive behaviour among the children with autism. Current treatment for these families is disjointed and costly. The need for the whole family support is supported by NICE recommendations, developments regarding children's service provision, research in this field and requests by families of children with autism. Despite evidence that family therapies can provide benefits to these families, its efficacy has not been subject to a randomised controlled trial. SAFE is a new family therapy intervention designed specifically for families of children with autism. We aim to establish the feasibility of running a fully powered randomised controlled trial to evaluate SAFE.

**Methods and analysis:** Families of children with autism aged 3-6 years will be invited to participate. Consenting participants will be randomised 2:1 to either SAFE + support as usual or support as usual alone. The primary outcome measure will be the Systemic CORE 15. Participants will also complete secondary outcome measures, which index changes in child behaviour, child-parent attachment, anxiety, and depression. Generic health economic outcome measures (EQ-5D-5L and CHU-9D) will also provide data on the feasibility of cost effectiveness analysis. Questionnaires will be completed at baseline and 32 weeks post allocation. Data on ability to identify, recruit, randomise, retain and collect data from families, acceptability of outcome measures, adherence of therapists and families to the intervention, appropriateness of resource use questionnaires and effectiveness of training will be collected for feasibility analysis. Qualitative data will also explore acceptability of SAFE and reasons for declining and withdrawing from the study.

**Ethics and dissemination:** The current trial protocol received ethical approval from the South West-Exeter Research Ethics Committee (Ref: 17/SW/0192).

**Trial registration number:** ISCTRN83964946 IRAS 213527

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The study addresses a gap in the available research data, and will produce important feasibility information to inform a fully powered randomised controlled trial.
- The study explores the feasibility of using measures of family function and a range of mental health measures.
- Quantitative feasibility data are complemented by qualitative focus groups and interviews.
- The study explores the feasibility of economic analysis measures in a population, which includes adults and their children with developmental disorders.
- The participants are recruited from two NHS Trusts in adjacent counties in the South West of England, leading to potential bias. A future randomised controlled trial will extend to centres across the UK including Scotland and Wales.

## INTRODUCTION

More than 1% of the UK population has a diagnosis of autism and numbers are rising. Families of children with autism present complex needs. Children with autism have impairments in social interaction, communication, and behavioural flexibility [1]. Autism is widely accepted to have a genetic component and the Broad Autism Phenotype is disproportionately represented among family members [2]. Mental health problems are experienced by more than 70% of individuals with autism and more than 50% of their parents [3,4]. Individuals with autism suffer from high levels of anxiety and depression compared to those with other developmental conditions [5,6,7]. Families of children with autism have higher rates of depression, anxiety, and social phobia, than families with typically developing children, or children with other developmental disorders [8]. Parents of children with autism are more likely to be hospitalised for mental disorders than parents of typically developing children [9]; and mothers of children with autism are reported to have higher unmet needs, more difficulties coping, and lower satisfaction with service interactions than mothers of children with other disabilities [10].

As families of children with autism often exhibit psychological morbidities alongside autism, costs of services to treat these problems are high [11,12]. Furthermore, untreated or unresponsive mental health problems impose societal costs making it hard for parents to interact effectively with services [13], worsening outcomes for children, and exacerbating the substantial economic burden of autism.

1  
2  
3 Explanations for high levels of affective disorders in these families include: stress  
4 associated with the condition of autism, genetic factors, and intergenerational family  
5 dynamics. Parenting children with autism involves stresses associated with maladaptive  
6 behaviour, lack of empathy, and atypical attachment behaviour displayed by children [14].  
7 Studies exploring the medical histories of family members indicate, however, that onset of  
8 affective disorders predate the birth of the child [8,15,16] suggesting that mental health  
9 difficulties cannot be wholly accounted for by stress involved in parenting. Depression and  
10 anxiety among family members have been tentatively linked to genetic factors independent  
11 of the Broad Autism Phenotype [17]. Few studies explore the intergenerational presence of  
12 affective disorder associated with autism and more work is needed in this area [8,15,16]. In  
13 particular, there are few studies, which question whether affective disorders combined with  
14 autistic traits among parents, pose an environmental risk for the development of autistic  
15 symptoms in children. Limited work demonstrates, however, that a child's risk of developing  
16 autism is doubled if both parents have a personality or psychiatric disorder [9]; and parents  
17 of children with autism report that lack of psychological wellbeing exacerbates maladaptive  
18 behaviour in their children [18]. A related body of research exists in the attachment  
19 literature, which suggests that emotional problems displayed by the parents of children with  
20 autism may be trans-generationally transmitted through insecure attachment patterns in  
21 families.  
22  
23  
24  
25  
26

27  
28 Our initial work [19] indicates that these parents have frequently experienced high levels of  
29 trauma and subsequent mental health problems. Unresolved trauma is known to impede  
30 parenting abilities and is associated with the development of severe forms of pathology in  
31 children. In addition, these families often encounter difficulties communicating needs to  
32 external agencies [20], which may trigger existing tendencies for negative affect. This is  
33 borne out by studies, reporting that families of children with autism are often characterised  
34 by a palpable air of tension [21]. Families of children with autism represent a high-risk  
35 group, yet treatment for these families is disjointed, costly and inadequate [22,23].  
36  
37  
38

39 A more joined-up approach is required which focuses on autism related need, coping with  
40 maladaptive behaviour and mental health difficulties by encouraging fundamental reflective  
41 functioning and improving family dynamics. The SAFE study should be placed in the  
42 context of NICE guidelines and recommendations [24,25] as well as developments  
43 regarding children's service provision proposed by the Munroe Report [26,27], and the  
44 'Future in Mind' children and young people's mental health report [28]. The SAFE study  
45 also reflects recommendations by other researchers working in the field [29,30]. Families of  
46 children with autism themselves highlight the importance of professionals working  
47 therapeutically with children and the wider family, in contrast to parents of children with  
48 conditions such as Down Syndrome who tend to stress the support needs of their child  
49 within educational and community settings [10].  
50  
51  
52  
53

54 SAFE is a systemic family therapy approach designed by experts to address autism related  
55 needs including mental health difficulties and problematic behaviour. Systemic Family  
56 Therapy is a well-recognized, evidence-based psychotherapeutic approach [31], which is  
57  
58  
59

recommended treatment for conditions such as Conduct Disorder, ADHD and Anorexia Nervosa [32]. Despite evidence that family therapies can provide benefits to children with autism and their parents [33,34] its efficacy for treating this condition has not been subject to a randomised controlled trial. A comprehensive search of clinical trial registries revealed no on-going trials assessing Systemic Family Therapy as a treatment for autism and associated mental health problems. This is surprising given guidelines and recommendations for care; the successful use of family therapies for a range of conditions and reports documenting key areas of concern for the UK autism community [35,36], which overwhelmingly show that families of children with autism want interventions which make real improvements to their daily life and sense of wellbeing. Consequently, the overarching aim of this study is to establish the feasibility of a definitive randomised controlled trial to evaluate Systemic Autism-related Family Enabling (SAFE) therapy for families of children with autism.

## METHODS AND ANALYSIS

### Participants and recruitment

Our target population are families of children with autism, who do not have an intellectual disability, between the ages of 3 and 16 years. Participants will be identified and recruited from two study research sites: Plymouth Hospitals NHS Trust (PHNT) Child Development Centre, and Royal Cornwall Hospitals NHS Trust Autism Spectrum Disorder Assessment Team (ASDAT). The pathways used to identify and recruit families will vary according to local practice, and the needs of the individual families being approached. Some families will receive a diagnosis during the SAFE recruitment period, and others will have been diagnosed up to 12 months before the SAFE study recruitment period starts.

Families with a diagnosis during the SAFE recruitment period will be approached by the diagnosing paediatrician, who will perform an initial eligibility check, invite the families to find out more and, if interested, refer the family to a member of the local SAFE study team. Families with a diagnosis before the SAFE study recruitment period will be identified as potentially eligible from clinic records by a suitably qualified member of the clinical team at each centre. All potential participant families will receive a participant information leaflet including an invitation to take part. All interested families will be able to speak to a member of the study team to discuss the study and have any questions answered.

The participant information leaflet will contain information about the study in plain English. Parents will be asked to explain the information to younger children in a way that is appropriate for their child and suggestions for how to do this will be contained in the leaflet. A home visit will be arranged by a member of the study team for those families who express interest in participating. During the visit, a research assistant will provide the families with more detailed participant information and seek consent.

### Inclusion criteria

- Family includes child with ASD, aged 3-16 years
- Diagnosis of autism spectrum disorder, severity level 1 or 2
- Diagnosed within 12 months of consenting to the study
- If other diagnoses are present, ASD must be primary diagnosis
- Family are willing to comply with study requirements

### Exclusion criteria

- Children with ASD severity level 3
- Children with ASD and intellectual impairment
- Serious concomitant illness in child or family, or other circumstances such that they are unable to comply with study requirements
- Families who may be a risk to safety of research staff
- Insufficient English language or capacity for parent/child to consent/assent to the study.

### Study design

This is a randomised, controlled, multi-centred feasibility study including children with autism and their families. Four cohorts of 9 families totalling 36 families will be recruited and each cohort will be randomised in a 2:1 ratio to receive support as usually employed (SUE) plus a programme of Systemic Autism-related Family Enabling (SAFE) therapy, or SUE alone, for a period of 16 weeks. Outcome assessors will be blinded to allocation. All participants will complete outcome measures at baseline and again at 32 weeks post-allocation via a face-to-face visit, hence each family will participate in the SAFE study for approximately eight months. The end date for the trial will be the date on which the last family completes the 32-week follow-up visit. An embedded qualitative study will collect information about the feasibility and acceptability of the intervention and the study itself.

### Outcome measures

Feasibility outcome measures:

- Ability to identify, recruit and randomise eligible families.
- Acceptability of proposed outcome measures and follow-up schedule to participants, and whether targets for loss to follow-up are achievable.
- Adherence of therapists and families to the intervention.
- Ability to gather quantitative data on outcomes
- Appropriateness of resource use questionnaires and preference-based instruments for this population
- Effectiveness and scalability of training arrangements



Clinical outcome measures:

- Scores on the proposed primary outcome measure, the Systemic CORE 15 (SCORE) [37]. This is a 15 item paper-based survey, which is a reliable, valid index of family functioning, and takes approximately 20 minutes to complete. SCORE is the primary measure of family functioning employed in CYP (Children and Young People's) Improving Access to Psychological Therapies national programme, and is the gold standard for assessing the impact of family therapy on quality of life in the UK [38]. Every able family member will be asked to complete the SCORE, and the same family members should complete the SCORE at baseline and 32 weeks.
- Scores on the proposed secondary outcome measures, which index changes in child behaviour, child-parent attachment, anxiety, and depression.
  - Patient Health Questionnaire – Somatic Anxiety Depressive Symptoms (PHQ-SADS). This comprises the PHQ-9 measuring depression and the GAD-7 measuring anxiety [39].
  - Coding of Attachment-Related Parenting for use with children with Autism - CARP-A [40]. The CARP-A is an observational measure of child's attachment behaviour towards their carer.
  - The Child Behaviour Checklist (CBCL) [41]. This is a 30-item paper-based survey, which detects emotional and behavioural problems.
  - The Reflective Functioning Questionnaire (RFQ) [42] measures ability to understand own and others' mental states.
  - Caregiving Helplessness Questionnaire [43] (CGHQ). This is a 26-item questionnaire designed to assess aspects of disorganised caregiving.
- Scores on generic health economic outcome measures will also provide data on the feasibility of cost effectiveness analysis:
  - EuroQol 5 dimensions (EQ-5D-5L). This is a standardised generic instrument for measuring health outcome.
  - Child Health Utility 9 Dimensions (CHU-9D). The CHU-9D is a paediatric generic preference based measure of health related quality of life.
  - Resource Use Questionnaire. A paper-based questionnaire completed by parent about his/her child's use of health care and social resources.
- Qualitative outcomes:
  - Acceptability of SAFE and the trial process for participants and therapists
  - Reasons for declining and withdrawing from the study

1  
2  
3 The qualitative component will employ focus groups and interviews to investigate four key  
4 aspects of the study experience: families' experiences of the study (including intervention),  
5 therapists' experiences of the intervention, reasons for eligible families declining, and  
6 reasons for families withdrawing from the study. After the 32-week assessments have been  
7 completed, participating families that have consented to participate in the qualitative focus  
8 groups will be given details of the time and location for the family feedback day. The family  
9 feedback day will involve several separate focus group sessions organised to take place  
10 over the period of a morning or an afternoon at a local venue for each centre including  
11 focus groups aimed specifically at parents and at children.  
12  
13  
14  
15

## 16 **The Intervention**

17  
18 SAFE is a manualised intensive programme of systemic family therapy designed to treat  
19 maladaptive autistic symptoms and mental health related difficulties encountered by  
20 families of children with autism. SAFE provides a toolkit of therapeutic activities based on  
21 Attachment Theory, established systemic practice and the known visual processing  
22 preferences of people with autism. Each therapy session will include two therapists with a  
23 minimum of intermediate family therapy level of qualification and four days training in SAFE  
24 principles. Between weeks 1 and 16, families allocated to the SAFE intervention will attend  
25 five 3-hour SAFE therapy sessions. Sessions 1 and 5 are multi-family sessions and will  
26 take place in a community setting. Sessions 2, 3 and 4 are for individual families and will  
27 take place in a community venue or the family home. The therapists will facilitate sessions  
28 which will be video recorded, as is usual practice for therapy sessions. The videotapes will  
29 be used by the therapists in supervision sessions and preparation for subsequent sessions.  
30  
31  
32  
33

34 Following completion of the therapy programme, families will attend a group follow-up  
35 session at 24 weeks post-allocation. Trained support workers from local voluntary groups  
36 will attend this follow-up session and will be invited to give the families information about  
37 continued support for families of children with autism through existing networks.  
38  
39

40 Each session will include the following assessments for families to complete:

- 41 1. Client Satisfaction Questionnaire (CSQ-8)
- 42 2. The Helpful Aspects of Therapy Questionnaire (HAT)
- 43 3. A Between Session Activity (BSA) homework activity Families will be given a pro-  
44 forma with key elements of the intervention as prompts for families to track strengths  
45 and difficulties in response to SAFE ideas.  
46  
47  
48  
49

50 At the end of each session the therapists will also complete a training checklist and  
51 questionnaire to monitor protocol adherence.  
52  
53  
54

## 55 **Support as usually employed**

56  
57  
58  
59  
60

1  
2  
3 Families will typically be offered a post-diagnosis follow-up appointment with the diagnosing  
4 paediatrician. Parents of children whose symptoms are not severe may be directed to local  
5 authority parenting classes. Classes such as 'Timeout for Autism' (Cornwall and the Isles of  
6 Scilly) and 'Understanding Autism' (Plymouth) focus on the features of Autism Spectrum  
7 Disorder, instructional parenting techniques and issues associated with education. Psycho-  
8 education may also be offered, with families being directed to relevant resources for e.g.  
9 The National Autism Society, Gateway ASD, and the NHS Child and Adolescent Mental  
10 Health Services (CAMHS). For families where a member is experiencing depression or  
11 anxiety, treatment varies and is not linked to autism-related care. Initial referral is often  
12 through the GP. Patients may receive Cognitive Behavioural Therapy as part of the  
13 Improved Access for Psychological Therapies service. They may also receive medication  
14 and in extreme cases a period of in-patient hospital treatment.  
15  
16  
17  
18  
19

### 20 **Proposed sample size**

21 In this feasibility trial no formal statistical testing of between group differences is planned.  
22 Sample size has been selected heuristically with the goal of i) demonstrating that  
23 participants can be recruited at a rate sufficient to run a full scale evaluation of SAFE at a  
24 later date; ii) demonstrating that it is possible to train therapists and deliver SAFE to  
25 patients within the study treatment settings, and iii) demonstrate that the data collection  
26 procedures are effective, and that the data collection is acceptable to the 36 families, and  
27 not overly burdensome.  
28  
29  
30  
31

### 32 **Data analysis**

33 Completed paper case report forms will be checked and signed by research staff before  
34 being sent to the Clinical Trials Unit (CTU). Original case report form pages will be posted  
35 to the CTU at agreed time points for double-data entry on to a password-protected  
36 database, with copies retained at the study site. Forms will be tracked using a web-based  
37 trial management system. Data will be analysed and presented as is appropriate for a  
38 feasibility study, in particular concentrating on descriptive analyses and undertaking no  
39 formal comparisons between groups. Reporting will follow the principles of the CONSORT  
40 Statement using the checklist and flowchart as recommended in the CONSORT extension  
41 for Randomized Pilot and Feasibility [44]. The flowchart will provide detail about the number  
42 of families approached, number eligible, number consenting, number randomised, number  
43 receiving allocated intervention and number assessed for outcome data at each time point.  
44 As appropriate, details will be given for individual members of the family, for example, how  
45 many family members there are and how many completed each questionnaire. Wherever  
46 possible, detailed reasons will be given for exclusions, loss to follow-up, non-completion of  
47 outcome measures etc.  
48  
49  
50  
51  
52  
53

54 Numbers will also be provided by centre and group, to inform the logistics of recruiting nine  
55 families prior to randomisation and following them up after randomisation. For those  
56  
57  
58  
59  
60

1  
2  
3 randomised to the SAFE intervention, adherence will be reported according to the number  
4 of group sessions attended and participation of individual family members at each of the  
5 therapy sessions. Completeness of data will be reported for each outcome measure at each  
6 relevant time point. Again this will be reported for individual family members as appropriate.  
7

8 For each outcome measure, the relevant scores will be calculated and presented  
9 descriptively by trial arm. Where available, published guidelines will be used to process,  
10 score and summarise the measures including, for example, the use of imputation in the  
11 event of missing items on a questionnaire. Summary measures will be calculated as  
12 appropriate, for example, means and standard deviations, medians and ranges, numbers  
13 and percentages in categories. These measures will be presented both for baseline and for  
14 the final follow-up. The only analysis contrasting the two groups will be an interval estimate  
15 in the form of a 95% confidence interval for the primary outcome, so that the plausibility for  
16 the effect size used in the sample size calculation for the full trial can be assessed. For this  
17 purpose the baseline values will be used in an Analysis of Covariance, with  
18 acknowledgment that no effects are included for group or therapist.  
19  
20  
21

22 Focus group interviews will be audio recorded and transcribed verbatim. Consequent  
23 qualitative data will be managed using proprietary computer assisted qualitative data  
24 analysis software, for example, Nvivo 10, and analysed thematically. Rigour of analysis will  
25 include 'respondent validation', whereby participants are provided with a summary of their  
26 transcript and analysis so that they can assess whether the interpretations being made  
27 about the data, accurately represent them. In addition, a second qualitative researcher will  
28 conduct an independent analysis of a subset of half of the focus group transcripts.  
29 Researchers will then meet to discuss and agree the findings, which will then be presented  
30 to the Family Consultation Group for discussion.  
31  
32  
33  
34  
35  
36

## 37 **ETHICS AND DISSEMINATION**

### 38 **Ethics and Safety**

39 Families of children with autism are a vulnerable group. The risks associated with  
40 participating in this study are however, considered minimal, with no adverse events  
41 anticipated in any participant. For those in the intervention group, there is a slight chance  
42 that the SAFE family therapy sessions could lead to an initial increase in family  
43 disagreements as family members learn how to change the way they solve problems and  
44 talk with one another. However, the purpose of the intervention is ultimately to equip  
45 families with skills to handle these difficulties by learning how to change the way they solve  
46 problems and improve their communication, and the SAFE family therapists will be  
47 available to provide support and will be trained to handle any emerging problems. Should  
48 any issues arise the SAFE family therapists will have access to two consultant clinical  
49 psychologists to provide further support and advice.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 During the trial the children with autism will remain in the care of the Child Development  
4 Centre or the Autism Spectrum Disorder Assessment Team and will have access to usual  
5 care should any unforeseen circumstances arise. Other members of the family will also  
6 continue to be able to seek care and advice from the GP or any other specialist services  
7 they are concurrently involved with.  
8  
9

### 11 **Informing potential participants of possible benefits and known risks**

12  
13 The participant information sheets and leaflets will provide potential participants with  
14 information about the possible benefits and risks of taking part in the trial. For example, the  
15 participants will be informed that a potential risk of receiving the SAFE therapy is that the  
16 sessions may evoke difficult emotions and feelings this could lead to family disagreement  
17 as they move towards change. The families will also be informed that benefits of the trial  
18 include the possibility of improved coping skills when faced with challenges and contribution  
19 to finding out if SAFE can progress to a national trial. Participants will be given the  
20 opportunity to discuss risks and benefits with a member of the research team prior to  
21 consenting to participate.  
22  
23  
24  
25

### 26 **Obtaining Informed consent from participants**

27  
28  
29 All participants will receive a leaflet and information sheet prior to consent. There are two  
30 versions of the information sheet, one for adults and one for children. In the leaflet parents  
31 are encouraged to explain the trial to their younger children and some guidance for doing  
32 this is provided. The information sheet states that the participants have the right to withdraw  
33 at any point during the trial and that data collected from them will be confidential. All  
34 participants will have a home-visit prior to consent from a member of the research team and  
35 will be able to ask questions or go through the information verbally.  
36  
37  
38  
39

### 40 **Data protection/confidentiality**

41  
42  
43 Participants will be given an identification number. The research team will ensure that  
44 participants' pseudo-anonymity is maintained on all documents. Data will be collected and  
45 stored in accordance with the current legal and regulatory documentation. Electronic study  
46 records will be stored in a SQL server database, stored on a restricted access, secure  
47 server maintained by Plymouth University. Data will be entered into the database via a  
48 bespoke web-based data entry system encrypted using SSL. Access to electronic data will  
49 be permission based, and at the discretion of the clinical trials unit data management team.  
50  
51

52  
53 Anonymised paper-based study data will be stored in locked filing cabinets within a locked  
54 office. Copies of study data retained at the lead study site will be securely stored for the  
55 duration of the study prior to archiving. Video data will be transported via encrypted memory  
56  
57  
58  
59

1  
2  
3 sticks and will be transferred to a password-protected computer. The clinical trials unit data  
4 team will have access to study data, including identifiable data. Other members of the study  
5 team and the trials unit will have restricted access to pseudo-anonymised study data.  
6 Access will be granted to the Sponsor and host institution on request, to permit study-  
7 related monitoring, audits and inspections.  
8  
9

## 10 **Research governance and the conduct of the trial**

11  
12 The trial will be conducted to protect the human rights and dignity of the participant as  
13 reflected in the Helsinki Declaration. An important factor in protecting the participants is  
14 ongoing consultation with the SAFE Family Consultation Group. A representative of this  
15 group is a member of the research team and is involved in decision-making processes. The  
16 research team including the family consultation group are proactive in minimising  
17 discomfort and risk for participants, respecting their wishes over science and society,  
18 respecting the right to withdraw and the need for families to have access to all relevant  
19 information.  
20  
21  
22  
23  
24

## 25 **Dissemination plans**

26  
27  
28 If the feasibility study demonstrates successful recruitment and an ability to deliver the  
29 intervention an important part the dissemination plan is to raise awareness of the need for a  
30 larger multi-centre trial. Targeted summaries of the findings and presentations will be  
31 disseminated to policy makers. The findings will also be broadly disseminated, but in a  
32 manner appropriate to a feasibility study. National conference presentations and published  
33 papers will be prepared to inform clinicians, academics and therapists about our feasibility  
34 results and generate interest in the future trial. Existing connections including the  
35 Association for Family Therapy, the National Autistic Society and the Institute of Family  
36 Therapy will be utilised to reach relevant audiences. The qualitative findings will also be  
37 published with detailed accounts of the families' reactions to SAFE and their views on its  
38 usefulness. A summary of study results in plain English will be available on the Peninsula  
39 Clinical Trials website.  
40  
41  
42  
43  
44  
45

## 46 **Clinical trials authorisation and ethical approval**

47  
48 Clinical trials authorisation is not required. The study has appropriate Research Ethics  
49 Committee (REC) approval from the South West-Exeter Research Ethics Committee (Ref:  
50 17/SW/0192) and approval from the Health Research Authority (HRA). The trial will be  
51 conducted in accordance with the protocol, the principles of the Declaration of Helsinki and  
52 ICH GCP. Any amendments of the protocol will be submitted to the Sponsor, HRA and REC  
53 for approval.  
54  
55  
56  
57  
58  
59  
60

### Trial sponsorship

The trial is sponsored by Plymouth Hospitals NHS Trust.

### Monitoring adverse events

The research team have mechanisms in place to report serious adverse events (SAE) related to mental health. If the CI considers that the SAE is not, or is unlikely to be, associated with the trial, the clinical trials unit will obtain a second assessment of causality from an independent assessor. Any SAE which in the opinion of either adjudicator is possibly related to the trial will be reported to the Research Ethics Committee within 15 days of the local research team having become aware of the event. All SAEs will be followed until either stabilised if chronic conditions or resolved.

### Trial Steering Committee

The Trial Steering Committee will include an independent chair and at two other independent members, along with the lead investigator and the other study collaborators including a parent representative. They will meet once a year.

### REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, Washington, DC 2013.
2. Sasson NJ, Lam KSL, Parlier M, et al. Autism and the broad autism phenotype: familial patterns and intergenerational transmission. *J Neurodev Disord* 2013; 5:11-18.
3. Dykens EM, Fisher MH, Taylor JL, et al. Reducing Distress in Mothers of Children with Autism and Other Disabilities: A Randomized Trial. *Pediatrics* 2014; 2013-3164.
4. Hallett V, Ronald A, Colvert, E, et al. Exploring anxiety symptoms in a large-scale twin study of children with autism spectrum disorders, their co-twins and controls. *Journal of Child Psychology and Psychiatry* 2013;54:1176-1185.
5. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. *J Autism Dev Disord* 2006;36: 863-870.
6. Kim JA, Szatmari P, Bryson SE, et al. The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. *Autism* 2000; 4:117-132.

- 1  
2  
3 7. Howlin P. Interventions for people with autism: recent advances. *Adv Psychiatr Treat*  
4 1997;3: 94-102.  
5
- 6  
7 8. Mazefsky CA, Folstein SE, Lainhart JE. Overrepresentation of Mood and Anxiety  
8 Disorders in Adults with Autism and Their First Degree Relatives: What Does it  
9 Mean? *Autism Res* 2008;1:193-197.  
10
- 11 9. Daniels JL, Forssen U, Hultman M, et al. Parental Psychiatric Disorders Associated With  
12 Autism Spectrum Disorders in the Offspring. *Pediatrics* 2008;121:1357-1162.  
13
- 14 10. Siklos S, Kerns KA. Assessing Need for Social Support in Parents of Children with  
15 Autism and Down Syndrome. *J Autism Dev Disord* 2008;36:921-933.  
16
- 17 11. McCrone P, Dhanasiri S, Patel A, et al. The cost of mental health care in England to  
18 2026. Executive Summary, London: The King's Fund. 2008  
19
- 20 12. Buescher AVS, Cidav Z, Knapp M, et al. Costs of Autism Spectrum Disorders in the  
21 United Kingdom and the United States. *JAMA Pediatr* 2014;e1-e8.  
22
- 23 13. Osborne LA, McHugh L, Saunders J, et al. Parenting Stress Reduces the Effectiveness  
24 of Early Teaching Interventions for Autistic Spectrum Disorders. *J Autism Dev*  
25 *Disord* 2008;38:1092-1103.  
26
- 27 14. Pisula E. Parenting Stress in Mothers and Fathers of Children with Autism Spectrum  
28 Disorders, A Comprehensive Book on Autism Spectrum Disorders, Dr. Mohammad-  
29 Reza Mohammadi (Ed.) 2011. Available from: [http://www.intechopen.com/books/a-  
30 comprehensive-  
31 bookon-  
32 autism-spectrum-disorders/parenting-stress-in-mothers-  
33 and-fathers-of-children-with-autismspectrum-disorders](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
34
- 35 15. Bolton PF, Pickles A, Murphy M, et al. Autism, affective and other psychiatric disorders:  
36 patterns of familial aggregation. *Psychological Medicine* 1998;28: 385-395.  
37
- 38 16. Demir T, Dogangun B, Karacetin G, et al. Psychiatric Disorders and Symptoms in  
39 Mothers of Children with Autistic Disorder. *Neurol Psychiatry Brain Res* 2008;15:1-5.  
40
- 41 17. Piven J, Palmer P. Psychiatric disorder and the broad autism phenotype: evidence from  
42 a family study of multiple-incidence autism families. *Am J Psychiatry* 1999;156:557-  
43 563.  
44
- 45 18. Nikmat AW, Ahmad M, Oon NL, et al. Stress and psychological wellbeing among  
46 parents of children with autism spectrum disorder. *ASEAN Journal of Psychiatry*  
47 2008;9:65-72.  
48
- 49 19. McKenzie R, Dallos R, Autism and Family Dynamics. Manuscript in preparation.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1
- 2
- 3 20. Konstantareas MK. Autistic, learning disabled and delayed children's impact on their
- 4 parents. *Can J Behav Sci* 1991;23:358-375.
- 5
- 6 21. Murphy M, Bolton PF, Pickles A, et al. Personality traits of the relatives of autistic
- 7 probands. *Psychol Med* 2000;30:1411-1424.
- 8
- 9
- 10 22. Blackledge JT, Hayes SC. Using Acceptance and Commitment Training in the Support
- 11 of Parents of Children Diagnosed with Autism. *Child & Family Behavior Therapy*,
- 12 2006:28:1-18.
- 13
- 14 23. Davis G. Lead Paediatric Psychologist, Plymouth Hospitals Trust. Personal
- 15 communication, September 10, 2014.
- 16
- 17
- 18 24. NICE guidelines [CG170] [https://www.nice.org.uk/guidance/cg170/chapter/patient-](https://www.nice.org.uk/guidance/cg170/chapter/patient-centred-care)
- 19 [centred-care](https://www.nice.org.uk/guidance/cg170/chapter/patient-centred-care)
- 20
- 21 25. NICE guidelines [CG128] <https://www.nice.org.uk/guidance/cg128>
- 22
- 23
- 24 26. Munroe E. The Munroe Review of Child protection: Final report, Dept. of Education, HM
- 25 Stationary Office, UK 2011.
- 26
- 27
- 28 27. Goodman S, Trowler I. Social work re-claimed: Innovative frameworks for child and
- 29 social work Practice. London: Jessica Kingsley 2012.
- 30
- 31 28. NHS England. Future in Mind: promoting, protecting and improving our children and
- 32 young people's mental health and wellbeing. Dept of Health Publication Gateway
- 33 Ref. No 02939, 2015.
- 34
- 35
- 36 29. IAPT | CYP IAPT Children and Young People's Project. (n.d.). Retrieved January 5,
- 37 2015, from <http://www.iapt.nhs.uk/cyp-iapt/>
- 38
- 39
- 40 30. Bromley J, Hare DJ, Davison K. et al. Mothers supporting children with autistic
- 41 spectrum disorders: Social support, mental health status and satisfaction with
- 42 services. *Autism* 2004;8:409-423.
- 43
- 44
- 45 31. Stratton P. Report On The Evidence Base Of Systemic Family Therapy. *Association for*
- 46 *Family Therapy* 2005.
- 47
- 48 32. Dallos R, Draper R. (4th Edn) An Introduction to Family Therapy. Maidenhead: Open
- 49 Univ. Press/McGraw Hill 2015.
- 50
- 51
- 52 33. Monteiro M. Family Therapy and the Autism Spectrum: Autism Conversations in
- 53 Narrative Practice. London: Routledge 2016.
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 34. Estrada AU, Pinosof WF. The effectiveness of family therapies for selected behavioural  
4 disorders of childhood. *J Marital Fam Ther* 1995;21: 403-424.  
5  
6 35. Pellicano E, Dinsmore A, Charman T. What should autism research focus upon?  
7 Community views and priorities from the United Kingdom. *Autism, Special Issue*  
8 *Article* 2014:1-15.  
9  
10 36. Wallace S, Parr J, Hardy, A. One in a hundred: Putting families at the heart of autism  
11 research. London: Autistica 2013.  
12  
13 37. Stratton P, Bland J, Janes E, et al. Developing an indicator of family function and a  
14 practicable outcome measure for systemic family and couple therapy: the SCORE.  
15 *Journal of Family Therapy* 2010;32:232-258.  
16  
17 38. SHIFT Self-Harm Intervention, Family Therapy: a randomised controlled trial of family  
18 therapy vs. treatment as usual for young people seen after second or subsequent  
19 episodes of self harm. Protocol Grant Number: 470772 HTA Reference Number:  
20 07/33/01, 2015.  
21  
22 39. Spitzer R L, Kroenke K, Williams JBW. The Patient Health Questionnaire Primary Care  
23 Study Group. Validation and utility of a self-report version of PRIME-MD: the PHQ  
24 Primary Care Study. *JAMA*, 282, 1999:1737-1744.  
25  
26 40. Blazey L. Coding of Attachment-Related Parenting for use with children with Autism  
27 (CARP-A). Manchester University 2007.  
28  
29 41. Moss E, Bureau J, Cyr C, et al. Correlates of attachment at age 3 Construct validity of  
30 the Preschool Attachment Classification System. *Dev. Psychol* 2004;40:323-334.  
31  
32 42. Fonagy P, Luyten P, Moulton-Perkins A, et al. Development and validation of a self-  
33 report measure of mentalizing: The Reflective Functioning Questionnaire. *PLOS*  
34 *ONE*. 2016;11(7):e0158678.  
35  
36 43. Solomon J, George C. (Eds.) Disorganised Attachment and Caregiving. Guilford: New  
37 York 2011.  
38  
39 44. CONSORT extension for Randomized Pilot and Feasibility Trials ([http://www.consort-  
40 statement.org/randomised-pilot-and-feasibilitytrials](http://www.consort-statement.org/randomised-pilot-and-feasibilitytrials)).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 **AUTHORS' CONTRIBUTIONS:** RM and HH were responsible for the overall development  
53 of the protocol. RM, HH, RD, CM, PE, AB and TV were involved in the conception and  
54 production of the study and the development of the initial protocol. PE and AB provided  
55 methodological expertise and advice on quantitative analysis PE provided statistical  
56  
57  
58  
59  
60

1  
2  
3 expertise. RD was the lead researcher on design of the intervention and the qualitative  
4 component. TV and CM advised on design and ethics, particularly from the participant  
5 perspective. All authors made substantial contributions to drafting, revision and approval of  
6 the document.  
7

8  
9 **FUNDING STATEMENT:** This work was supported by the National Institute for Health  
10 Research (NIHR) grant number: PB-PG-0815-20058  
11

12 **COMPETING INTERESTS STATEMENT:** Contributors are co-applicants or employed  
13 research staff on the SAFE project, which receives funds from both NIHR and Autistica.  
14 Professor Rudi Dallos holds joint Intellectual Property rights for the SAFE intervention with  
15 The University of Plymouth. No other issues were raised with regard to competing interests.  
16  
17

18 **PROVENANCE AND PEER REVIEW:** Not commissioned; externally peer reviewed.  
19

20  
21 **DATA SHARING STATEMENT:** Further details of the study protocol can be requested  
22 from the corresponding author.  
23

---



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Front page
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Front page
	2b	All items from the World Health Organization Trial Registration Data Set	Front page, 6, 9
Protocol version	3	Date and version identifier	Front page
Funding	4	Sources and types of financial, material, and other support	34
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	6
	5b	Name and contact information for the trial sponsor	6
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	5
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	30 - 32

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	10 -11
	6b	Explanation for choice of comparators	29 - 30
Objectives	7	Specific objectives or hypotheses	11 - 12
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	12

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	16
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	16
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	21 - 22
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	21
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	21, 30
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	22
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14 - 15
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	19

1  
2  
3 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 29 - 30  
4 clinical and statistical assumptions supporting any sample size calculations

5  
6 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 20  
7

8 **Methods: Assignment of interventions (for controlled trials)**  
9

10 Allocation:

11 Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 29 - 30  
12 factors for stratification. To reduce predictability of a random sequence, details of any planned restriction  
13 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants  
14 or assign interventions  
15

16  
17 Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 19 - 20  
18 opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned  
19  
20

21 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 20  
22 interventions  
23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 20 - 21  
25 assessors, data analysts), and how  
26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's 20 - 21  
28 allocated intervention during the trial  
29  
30

31 **Methods: Data collection, management, and analysis**  
32

33 Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 27 - 29  
34 processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of  
35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.  
36 Reference to where data collection forms can be found, if not in the protocol  
37

38 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 24 - 25  
39 collected for participants who discontinue or deviate from intervention protocols  
40  
41  
42  
43  
44

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	28
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	29 - 30
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	25 - 26
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	29 - 30
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	31 - TSC performing DMC role.
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	33
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	26 - 27
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	30 - 31
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	32 - 33
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	32



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	18
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	23
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	28 - 29
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	29
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	33
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	33 - 34
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40



# BMJ Open

## **SAFE, a new therapeutic intervention for families of children with autism: study protocol for a feasibility randomised controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025006.R1
Article Type:	Protocol
Date Submitted by the Author:	08-Oct-2018
Complete List of Authors:	McKenzie, Rebecca; University of Plymouth, Institute of Education Dallos, Rudi; Department of Clinical Psychology, University of Plymouth Hancocks, Helen Vickery, Patricia; Plymouth University, Peninsula Clinical Trials Unit Ewings, Paul; Research Design Service, Research Office Barton, Andy; South West Research Design Service Vassallo, Tara Myhill, Craig
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Public health, Pathology, Research methods
Keywords:	autism, family therapy, intervention, feasibility

SCHOLARONE™  
Manuscripts

1  
2  
3 **SAFE, a new therapeutic intervention for families of children with autism:**  
4 **study protocol for a feasibility randomised controlled trial**  
5  
6  
7

8 Rebecca McKenzie<sup>1</sup>, Rudi Dallos<sup>1</sup>, Helen Hancocks<sup>2</sup>, Jane Vickery<sup>2</sup>, Paul Ewings<sup>3</sup>, Andy  
9 Barton<sup>3</sup>, Tara Vassallo<sup>1</sup>, Craig Myhill<sup>1</sup>  
10  
11  
12  
13  
14  
15

16 Author affiliations  
17

- 18 1. Plymouth University. Plymouth UK
- 19 2. Peninsula Clinical Trials Unit, Plymouth University. Plymouth UK
- 20 3. NIHR Research Design Service. South West. UK

21 Correspondence to: Dr Rebecca McKenzie [rebecca.mckenzie@plymouth.ac.uk](mailto:rebecca.mckenzie@plymouth.ac.uk)  
22  
23  
24  
25

26 Key words: Family Therapy, autism, intervention, feasibility, mental health  
27  
28  
29  
30  
31  
32

33 Word count: 5903 excluding title page, abstract and references  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Incidence of autistic traits, mental health problems, stress and poor coping is high among family members of children with autism. These problems are coupled with challenging behaviour among children with autism. Current treatment for these families is disjointed and costly. The need for whole family support is supported by NICE recommendations, developments regarding children's service provision, research and requests by families of children with autism. Despite evidence that family therapies can provide benefits to these families, its efficacy has not been subject to a randomised controlled trial. SAFE is a new family therapy intervention designed specifically for families of children with autism. We aim to establish the feasibility of running a fully powered randomised controlled trial to evaluate SAFE.

**Methods and analysis:** Families of children with autism aged 3-16 years will be invited to participate. Consenting participants will be randomised 2:1 to either SAFE + support as usual or support as usual alone. The proposed primary outcome measure for the main trial will be the Systemic CORE 15. Participants will also complete proposed secondary outcome measures, indexing changes in child behaviour, child-parent attachment, anxiety, and depression. Generic health economic outcome measures (EQ-5D-5L and CHU-9D) will also provide data on the feasibility of cost effectiveness analysis. Questionnaires will be completed at baseline and 32 weeks post allocation. Data on ability to identify, recruit, randomise, retain and collect data from families, acceptability of outcome measures, adherence of therapists and families to the intervention, appropriateness of resource use questionnaires and effectiveness of training will be collected for feasibility analysis. Qualitative data will also explore acceptability of SAFE and reasons for declining and withdrawing from the study.

**Ethics and dissemination:** The current trial protocol received ethical approval from the South West-Exeter Research Ethics Committee (Ref: 17/SW/0192).

**Trial registration number:** ISCTRN83964946 IRAS 213527

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The study addresses a gap in the available research data, and will produce important feasibility information to inform a fully powered randomised controlled trial.
- The study explores the feasibility of using measures of family function and a range of mental health measures.
- Quantitative feasibility data are complemented by qualitative focus groups and interviews.
- The study explores the feasibility of economic analysis measures in a population, which includes adults and their children with developmental disorders.
- The participants are recruited from two NHS Trusts in adjacent counties in the South West of England, leading to potential bias. A future randomised controlled trial will extend to centres across the UK including Scotland and Wales.

## INTRODUCTION

More than 1% of the UK population has a diagnosis of autism [1]. Families of children with autism present complex needs. Children with autism have impairments in social interaction, communication, and behavioural flexibility [2]. Autism is widely accepted to have a genetic component and the Broad Autism Phenotype is disproportionately represented among family members [3]. Mental health problems are experienced by more than 70% of individuals with autism and more than 50% of their parents [4,5]. Individuals with autism suffer from high levels of anxiety and depression compared to those with other developmental conditions [6,7,8]. Families of children with autism have higher rates of depression, anxiety, and social phobia, than families with typically developing children, or children with other developmental disorders [9]. Parents of children with autism are more likely to be hospitalised for mental disorders than parents of typically developing children [10]; and mothers of children with autism are reported to have higher unmet needs, more difficulties coping, and lower satisfaction with service interactions than mothers of children with other disabilities [11]. Aside from these reported difficulties, families of children with autism can have positive family experiences, sense of wellbeing [12] and positive perceptions of their children [13]. Despite challenges, autism can be seen as enhancing family experience and some parents recognise that parenting a child with autism has added joy to their lives [14], made them more appreciative [15], more patient and compassionate [16].

As families of children with autism often exhibit psychological morbidities alongside autism, costs of services to treat these problems are high [17,18]. Furthermore, untreated or unresponsive mental health problems impose societal costs making it hard for parents to interact effectively with services [19], potentially worsening outcomes for children and exacerbating the substantial economic burden of autism [18].

1  
2  
3 Explanations for high levels of affective disorders in these families include: stress  
4 associated with the condition of autism, genetic factors, and intergenerational family  
5 dynamics. Parenting children with autism involves stresses associated with challenging  
6 behaviour, lack of Theory of Mind, and atypical attachment behaviour displayed by children  
7 [20]. Studies exploring the medical histories of family members indicate, however, that  
8 onset of affective disorders predate the birth of the child [9,21,22] suggesting that mental  
9 health difficulties cannot be wholly accounted for by stress involved in parenting.  
10 Depression and anxiety among family members have been tentatively linked to genetic  
11 factors independent of the Broad Autism Phenotype [23]. Few studies explore the  
12 intergenerational presence of affective disorder associated with autism and more work is  
13 needed in this area [9,21,22]. In particular, there are few studies which question whether  
14 affective disorders combined with autistic traits among parents pose an environmental risk  
15 for the development of autistic symptoms in children. Limited work demonstrates, however,  
16 that a child's risk of developing autism is doubled if both parents have a personality or  
17 psychiatric disorder [11]; and parents of children with autism report that lack of  
18 psychological wellbeing exacerbates maladaptive behaviour in their children [24].  
19  
20  
21  
22  
23

24 Previous studies demonstrate that experience of trauma and abuse among women is  
25 associated with elevated risk of autism developing in their subsequent offspring [25,26].  
26 Hence mothers of children with autism are more likely than the general population to be  
27 coping with previous traumatic events. Unresolved trauma is known to impede parenting  
28 abilities and is associated with the development of severe forms of pathology in children. In  
29 addition, these families often encounter difficulties communicating needs to external  
30 agencies [27], which may trigger existing tendencies for negative affect. Families of children  
31 with autism can experience positive family life, cope well with difficulties and enjoy good  
32 relationships with their children but they represent a high-risk group, for whom treatment is  
33 disjointed, costly and inadequate [28,29].  
34  
35  
36  
37

38 A more joined-up approach is required which focuses on autism related need, coping with  
39 challenging behaviour and mental health difficulties by encouraging fundamental reflective  
40 functioning and improving family dynamics. The SAFE study should be placed in the  
41 context of NICE guidelines and recommendations [30,31] as well as developments  
42 regarding children's service provision proposed by the Munroe Report [32,33], and the  
43 'Future in Mind' children and young people's mental health report [34]. The SAFE study  
44 also reflects recommendations by other researchers working in the field [35,36]. Families of  
45 children with autism themselves highlight the importance of professionals working  
46 therapeutically with children and the wider family, in contrast to parents of children with  
47 conditions such as Down Syndrome who tend to stress the support needs of their child  
48 within educational and community settings [10].  
49  
50  
51

52 SAFE is a systemic family therapy approach designed by experts to address autism related  
53 needs including mental health difficulties and problematic behaviour. Systemic Family  
54 Therapy is a well-recognized, evidence-based psychotherapeutic approach [37], which is  
55 recommended treatment for conditions such as Conduct Disorder, ADHD and Anorexia  
56  
57  
58  
59  
60

1  
2  
3 Nervosa [38]. Despite evidence that family therapies can provide benefits to children with  
4 autism and their parents [39,40] its efficacy for treating this condition has not been subject  
5 to a randomised controlled trial. A comprehensive search of clinical trial registries revealed  
6 no on-going trials assessing Systemic Family Therapy as a treatment for autism and  
7 associated mental health problems. This is surprising given guidelines and  
8 recommendations for care; the successful use of family therapies for a range of conditions  
9 and reports documenting key areas of concern for the UK autism community [41,42], which  
10 overwhelmingly show that families of children with autism want interventions which make  
11 real improvements to their daily life and sense of wellbeing. Consequently, the overarching  
12 aim of this study is to establish the feasibility of a definitive randomised controlled trial to  
13 evaluate Systemic Autism-related Family Enabling (SAFE) therapy for families of children  
14 with autism.  
15  
16  
17  
18  
19

## 20 **METHODS AND ANALYSIS**

### 21 **Participants and recruitment**

22  
23  
24  
25 Our target population are families of children with autism, who do not have an intellectual  
26 impairment, between the ages of 3 and 16 years. SAFE is designed to have a visual play-  
27 based approach, but children gain most from the intervention if they can understand and  
28 communicate their responses to SAFE activities. Pilot data suggest that SAFE will be most  
29 effective and accessible for children who do not have severe symptoms or an intellectual  
30 impairment. Those children who were non-verbal and/or had severe communication  
31 difficulties found it difficult to engage with some activities. For this feasibility study,  
32 therefore, our target population is families of children with autism severity level 1 or 2 with  
33 no intellectual impairment. Future plans for SAFE include the development of a sister  
34 intervention which has extended non-verbal elements based on Intensive Interaction and is  
35 designed specifically to support families of children with autism and an intellectual  
36 impairment. This feasibility study focuses on families of children of school-age which fits  
37 with the priorities of one of our secondary sources of funding. Background research  
38 exploring diagnostic data for our proposed centres for the previous two years revealed no  
39 children without intellectual impairment diagnosed before the age of 3 years. Consequently,  
40 we focused on the 3-16 age group.  
41  
42  
43  
44  
45  
46

47 Participants will be identified and recruited from two study research sites: University  
48 Hospitals Plymouth NHS Trust (PHNT) Child Development Centre, and Cornwall  
49 Partnership NHS Foundation Trust Autism Spectrum Disorder Assessment Team (ASDAT).  
50 The pathways used to identify and recruit families will vary according to local practice, and  
51 the needs of the individual families being approached. Some families will receive a  
52 diagnosis during the SAFE recruitment period, and others will have been diagnosed up to  
53 12 months before the SAFE study recruitment period starts.  
54  
55

56 Families with a diagnosis during the SAFE recruitment period will be approached by the  
57  
58  
59

1  
2  
3 diagnosing paediatrician, who will perform an initial eligibility check, invite the families to  
4 find out more and, if interested, refer the family to a member of the local SAFE study team.  
5 Families with a diagnosis before the SAFE study recruitment period will be identified as  
6 potentially eligible from clinic records by a suitably qualified member of the clinical team at  
7 each centre. Clinical staff in our centres and the surrounding areas are responsible for  
8 diagnosis of the children within our participating families. If the child is recruited from a  
9 diagnostic centre the clinical staff also assess eligibility.  
10  
11

12  
13 All potential participant families will receive a participant information leaflet including an  
14 invitation to take part. All interested families will be able to speak to a member of the study  
15 team to discuss the study and have any questions answered. The participant information  
16 leaflet will contain information about the study in plain English. Parents will be asked to  
17 explain the information to younger children in a way that is appropriate for their child and  
18 suggestions for how to do this will be contained in the leaflet. A home visit will be arranged  
19 by a member of the study team for those families who express interest in participating.  
20 During the visit, a research assistant will provide the families with more detailed participant  
21 information and seek consent.  
22  
23  
24

### 25 **Community pathway**

26 Participants that have received either a new diagnosis, or a diagnosis within the last 12  
27 months will also be approached through community groups, using a recruitment poster,  
28 invitation letter, reply slip, participant information leaflet, and freepost envelope. These  
29 participants will be contacted by a member of the research team by telephone at which time  
30 they will discuss the study and answer questions. The families will also be asked to consent  
31 to providing the original NHS diagnosis letter, which will be used by the research staff to  
32 determine eligibility to participate in the study, and legal guardianship at the first home visit.  
33  
34  
35

### 36 **Inclusion criteria**

- 37 • Family includes child with ASD, aged 3-16 years
  - 38 • Diagnosis of autism spectrum disorder, severity level 1 or 2
  - 39 • Diagnosed within 12 months of consenting to the study
  - 40 • If other diagnoses are present, ASD must be primary diagnosis
  - 41 • Family are willing to comply with study requirements
- 42  
43  
44

### 45 **Exclusion criteria**

- 46 • Children with ASD severity level 3
  - 47 • Children with ASD and intellectual impairment\*
  - 48 • Serious concomitant illness in child or family, or other circumstances such that they  
49 are unable to comply with study requirements
  - 50 • Families who may be a risk to safety of research staff (This will be assessed by the  
51 clinical and research staff on the basis of clinical records, diagnosis letter and  
52 contact prior to the first home visit).
- 53  
54  
55  
56  
57  
58  
59  
60

- Insufficient English language or capacity for parent/child to consent/assent to the study.

\* Intellectual impairment will be assessed by the clinical staff as present on the basis of any of the following criteria:

- The child has a comorbid diagnosis of intellectual disability
- Diagnosis specifies "with accompanying intellectual impairment"
- The child has been identified as requiring very substantial support (severity level 3) according to DSM-5 criteria for ASD
- The child is being educated in a special school for children with intellectual disabilities
- The child has an IQ of 70 or below

## Study design

This is a randomised, controlled, multi-centred feasibility study including children with autism and their families. A total of 36 families will be recruited in four cohorts and each cohort will be randomised in a 2:1 ratio to receive support as usually employed (SUE) plus a programme of Systemic Autism-related Family Enabling (SAFE) therapy, or SUE alone, for a period of 16 weeks. Advantages of 2:1 allocation include:

- Increased appeal for patients deciding whether to consent to randomisation.
- Increased ability to test training of therapists, and ability to deliver high-fidelity treatment.
- Minimal reduction in statistical power for between-groups comparisons in a full-scale evaluation.
- Increased ability to recruit required number of families within an area before randomising; which will be closer to the figure needed if and when the intervention is implemented.

Outcome assessors will be blinded to allocation. All participants will complete outcome measures at baseline and again at 32 weeks post-allocation via a face-to-face visit, hence each family will participate in the SAFE study for approximately eight months. An embedded qualitative study will collect information about the feasibility and acceptability of the intervention and the study itself. Qualitative data will be collected at a Family Feedback Day after the 32 week post-allocation visits have been completed. The end date for the trial will be the date on which the last family completes the Family Feedback Day.

## Outcome measures

Feasibility outcome measures:

- Ability to identify, recruit and randomise eligible families.



- Acceptability of proposed outcome measures and follow-up schedule to participants, and whether targets for loss to follow-up are achievable.
- Adherence of therapists and families to the intervention.
- Ability to gather quantitative data on outcomes
- Appropriateness of resource use questionnaires and preference-based instruments for this population
- Effectiveness and scalability of training arrangements

#### Clinical outcome measures:

- Scores on the proposed primary outcome measure, the Systemic CORE 15 (SCORE) [43]. This is a 15 item paper-based survey, which has been shown to have good internal reliability (Cronbach's  $\alpha = .89$ ) [44] and to be a valid index of family functioning, taking approximately 20 minutes to complete. The SCORE is the primary measure of family functioning employed in CYP (Children and Young People's) Improving Access to Psychological Therapies national programme, and is the gold standard for assessing the impact of family therapy on quality of life in the UK [45]. Every able family member will be asked to complete the SCORE, and the same family members should complete the SCORE at baseline and 32 weeks. The SCORE-15 is freely available online [46].
- Scores on the proposed secondary outcome measures, which index changes in child behaviour, child-parent attachment, anxiety, and depression.
  - Patient Health Questionnaire – Somatic Anxiety Depressive Symptoms (PHQ-SADS). This comprises the PHQ-9 (estimated internal reliability Cronbach's  $\alpha = .86-.89$ ) [47] measuring depression and the GAD-7 (estimated internal reliability  $\alpha = .92$ ) [47] measuring anxiety [48].
  - Adapted mutuality sub-scale of the Coding of Attachment-Related Parenting for use with children with Autism - CARP-A [49]. The CARP-A is a validated observational measure of a child with autism's attachment behaviour towards their carer. The CARP-A Mutuality subscale is reported as having inter-rater reliability of .74 [50].
  - The Child Behaviour Checklist (CBCL) [51]. This is a 30-item paper-based survey, which detects emotional and behavioural problems. Reasonable internal reliability is reported for each of three scales, given that some scales only have 4 items: 1. Competence scales (Cronbach's  $\alpha = .63-.79$ ) 2. Problems scales (Cronbach's  $\alpha = .78-.97$ ) and 3. DSM orientated scales (Cronbach's  $\alpha = .72-.91$ ) [52].
  - The Reflective Functioning Questionnaire (RFQ) [53] measures ability to understand own and others' mental states (Test-retest reliability coefficients are reported as 0.84) [53].
  - Caregiving Helplessness Questionnaire [54] (CGHQ). This is a 26-item questionnaire designed to assess aspects of disorganised caregiving. The

CGHQ includes three subscales with reasonable internal reliability given the number of items: 1. Mother Helpless ( $\alpha = .86$ ) includes 7 items, 2. Mother-Child Frightened ( $\alpha = .66$ ) includes 6 items, 3. Child Caregiving ( $\alpha = .64$ ) includes 6 items [55].

- Scores on generic health economic outcome measures will also provide data on the feasibility of cost effectiveness analysis:
  - EuroQol 5 dimensions (EQ-5D-5L). This is a standardised generic instrument for measuring health outcome.
  - Child Health Utility 9 Dimensions (CHU-9D). The CHU-9D is a paediatric generic preference based measure of health related quality of life.
  - Resource Use Questionnaire (RUQ). A paper-based questionnaire completed by parent about his/her child's use of health care and social resources. The RUQ is designed to identify the NHS and Social Care resource use for the economic evaluation. It includes items to establish number and type of health resources being used, such as number of GP visits or number of days in hospital. Resource Use Questionnaire completion will be matched with medical records for a subgroup of families, which will help to develop strategies to minimise missing data in the future definitive trial.
  
- Qualitative outcomes:
  - Acceptability of SAFE and the trial process for participants and therapists
  - Reasons for declining and withdrawing from the study

The qualitative component will employ focus groups and interviews to investigate four key aspects of the study experience: families' experiences of the study (including intervention and potential harm of the intervention), therapists' experiences of the intervention, reasons for eligible families declining, and reasons for families withdrawing from the study. After the 32-week assessments have been completed, participating families that have consented to participate in the qualitative focus groups will be given details of the time and location for the family feedback day. The family feedback day will involve several separate focus group sessions organised to take place over the period of a morning or an afternoon at a local venue for each centre including focus groups aimed specifically at parents and at children.

### **The Intervention**

SAFE is a manualised intensive programme of systemic family therapy designed to treat maladaptive autistic symptoms and mental health related difficulties encountered by families of children with autism. SAFE provides a toolkit of therapeutic activities based on Attachment Theory, established systemic practice and the known visual processing preferences of people with autism [For example, 56,57,58]. Each therapy session will include two therapists with a minimum of intermediate family therapy level of qualification

1  
2  
3 and four days training in SAFE principles. Prior to the therapy sessions parents allocated to  
4 SAFE will complete an adapted version of the Parent Development Interview [59], which  
5 will provide therapists with background information on family experience. The reflective  
6 functioning questions of this interview will also be revisited as an opportunity to discuss  
7 change at the 24-week follow up. Between weeks 1 and 16, families allocated to the SAFE  
8 intervention will attend five 3-hour SAFE therapy sessions. Sessions 1 and 5 are multi-  
9 family sessions and will take place in a community setting. Sessions 2, 3 and 4 are for  
10 individual families and will take place in a community venue or the family home. The  
11 therapists will facilitate sessions which will be video recorded, as is usual practice for  
12 therapy sessions. The videotapes will be used by the therapists in supervision sessions and  
13 preparation for subsequent sessions.  
14  
15  
16

17  
18 Following completion of the therapy programme, families will attend a group follow-up  
19 session at 24 weeks post-allocation. Families will discuss any changes they have  
20 encountered focusing on their ability to be reflective about challenges faced and solutions  
21 tried. Trained support workers from local voluntary groups will attend this follow-up session  
22 and will be invited to give the families information about continued support for families of  
23 children with autism through existing networks.  
24  
25

26 Each session will include the following assessments for families to complete:  
27  
28

- 29 1. Client Satisfaction Questionnaire (CSQ-8)
- 30 2. The Helpful Aspects of Therapy Questionnaire (HAT)
- 31 3. A Between Session Activity (BSA) homework activity Families will be encouraged to  
32 complete a pro-forma with key elements of the intervention as prompts for families to  
33 track strengths and difficulties in response to SAFE ideas. Completion of the BSA  
34 will be recorded.  
35  
36

37  
38 At the end of each session the therapists will also complete a training checklist and  
39 questionnaire to monitor protocol adherence.  
40  
41

### 42 **Support as usually employed**

43  
44 Families will typically be offered a post-diagnosis follow-up appointment with the diagnosing  
45 paediatrician. Parents of children whose symptoms are not severe may be directed to local  
46 authority parenting classes. Classes such as 'Timeout for Autism' (Cornwall and the Isles of  
47 Scilly) and 'Understanding Autism' (Plymouth) focus on the features of Autism Spectrum  
48 Disorder, instructional parenting techniques and issues associated with education. Psycho-  
49 education may also be offered, with families being directed to relevant resources for e.g.  
50 The National Autism Society, Gateway ASD, and the NHS Child and Adolescent Mental  
51 Health Services (CAMHS). For families where a member is experiencing depression or  
52 anxiety, treatment varies and is not linked to autism-related care. Initial referral is often  
53 through the GP. Patients may receive Cognitive Behavioural Therapy as part of the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Improved Access for Psychological Therapies service. They may also receive medication  
4 and in extreme cases a period of in-patient hospital treatment.  
5  
6

7 A study schema is presented in Figure 1. below.  
8  
9

10 (Place Figure 1 here)  
11

### 12 **Proposed sample size**

13  
14 In this feasibility trial no formal statistical testing of between group differences is planned.  
15 Sample size has been selected heuristically with the goal of i) demonstrating that  
16 participants can be recruited at a rate sufficient to run a full scale evaluation of SAFE at a  
17 later date; ii) demonstrating that it is possible to train therapists and deliver SAFE to  
18 patients within the study treatment settings, and iii) demonstrate that the data collection  
19 procedures are effective, and that the data collection is acceptable to the 36 families, and  
20 not overly burdensome.  
21  
22  
23

### 24 **Data analysis**

25  
26 Completed paper case report forms will be checked and signed by research staff before  
27 being sent to the Peninsula Clinical Trials Unit (CTU). Original case report form pages will  
28 be posted to the CTU at agreed time points for double-data entry on to a password-  
29 protected database, with copies retained at the study site. Forms will be tracked using a  
30 web-based trial management system. Data will be analysed and presented as is  
31 appropriate for a feasibility study, in particular concentrating on descriptive analyses and  
32 undertaking no formal comparisons between groups. Reporting will follow the principles of  
33 the CONSORT Statement using the checklist and flowchart as recommended in the  
34 CONSORT extension for Randomized Pilot and Feasibility [60]. The flowchart will provide  
35 detail about the number of families approached, number eligible, number consenting,  
36 number randomised, number receiving allocated intervention and number assessed for  
37 outcome data at each time point. As appropriate, details will be given for individual  
38 members of the family, for example, how many family members there are and how many  
39 completed each questionnaire. Wherever possible, detailed reasons will be given for  
40 exclusions, loss to follow-up, non-completion of outcome measures etc.  
41  
42  
43  
44  
45

46  
47 Numbers will also be provided by centre and group, to inform the logistics of recruiting nine  
48 families prior to randomisation and following them up after randomisation. For those  
49 randomised to the SAFE intervention, adherence will be reported according to the number  
50 of group sessions attended and participation of individual family members at each of the  
51 therapy sessions. Completeness of data will be reported for each outcome measure at each  
52 relevant time point. Again this will be reported for individual family members as appropriate.  
53

54 For each outcome measure, the relevant scores will be calculated and presented  
55 descriptively by trial arm. Where available, published guidelines will be used to process,  
56  
57  
58

1  
2  
3 score and summarise the measures including, for example, the use of imputation in the  
4 event of missing items on a questionnaire. Summary measures will be calculated as  
5 appropriate, for example, means and standard deviations, medians and ranges, numbers  
6 and percentages in categories. These measures will be presented both for baseline and for  
7 the final follow-up. The only analysis contrasting the two groups will be an interval estimate  
8 in the form of a 95% confidence interval for the primary outcome, so that the plausibility for  
9 the effect size used in the sample size calculation for the full trial can be assessed. For this  
10 purpose the baseline values will be used in an Analysis of Covariance, with  
11 acknowledgment that no effects are included for group or therapist.  
12  
13

14 Focus group interviews will be audio recorded and transcribed verbatim. Consequent  
15 qualitative data will be managed using proprietary computer assisted qualitative data  
16 analysis software, for example, Nvivo 10, and analysed thematically [61,62]. Rigour of  
17 analysis will include 'respondent validation', whereby participants are provided with a  
18 summary of their transcript and analysis so that they can assess whether the interpretations  
19 being made about the data, accurately represent them. In addition, a second qualitative  
20 researcher will conduct an independent analysis of a subset of half of the focus group  
21 transcripts. Researchers will then meet to discuss and agree the findings, which will then be  
22 presented to the Family Consultation Group for discussion.  
23  
24  
25  
26  
27

## 28 **Patient and Public Involvement**

29  
30 Families of children with autism initiated the development of this project by communicating  
31 their complex needs and dissatisfaction with current service provision through the Plymouth  
32 Autism Network. This Network was set up by the Chief Investigator in 2011 to bring  
33 clinicians, carers, academics and individuals with autism together to share ideas, research  
34 findings and experiences. We further explored the challenges facing families of children  
35 with autism by conducting in-depth interviews and surveying over 90 families regarding their  
36 needs and the treatment they received post-diagnosis. Less than 9% of families agreed that  
37 current treatment helped with the problems they face. Our survey revealed a strong need  
38 for interventions, which support the whole family.  
39  
40  
41

42 This pilot data led to the development of a research team within the Welcome Research  
43 Hub at Plymouth University, which included a Family Consultation Group. Our Family  
44 Consultation Group worked with us to develop and refine the SAFE intervention prior to the  
45 current project. These families have also contributed to the creation of a recruitment and  
46 treatment plan, which will be manageable for families. They have offered advice about how  
47 it is best to communicate with families at the start of the study and as it progresses. In  
48 addition, the Family Consultation Group representative is a co-applicant on this  
49 study.  
50  
51  
52

53  
54 Our Family Consultation Group will continue to be essential members of the team and work  
55 as an advisory group throughout the feasibility study and beyond. We see our Family  
56 Consultation Group as experts in their own lives and the lives of families with similar  
57  
58  
59

1  
2  
3 challenges. For this reason we feel our role is to work with them in a supportive manner as  
4 collaborators. Their contribution is valuable in the same way as other experts on the team  
5 and we aim to facilitate one another. As stated above, the Family Consultation Group have  
6 been active in contributing to the research plan. Their input is of particular value in  
7 developing recruitment procedures, designing participant information packs and providing  
8 information about potential barriers to retention. We have also worked with them to prepare  
9 and deliver a training programme for research staff and therapists. With their help we have  
10 trained recruited staff work in a sensitive and informed manner with participants. We also  
11 value their input in interpreting and reporting data; in particular commenting on possible  
12 ways to overcome challenges for the main RCT.  
13  
14  
15

16 Our families can help by identifying local networks and sharing their experience with new  
17 groups. Our Family Consultation Group are proactive campaigners for change and have  
18 extensive knowledge of existing bodies such as the National Autistic Society. They can also  
19 provide a family-centred perspective on research outcomes. They are, therefore, well-  
20 placed to collaborate with us in planning next steps and disseminating findings at local and  
21 national levels.  
22  
23  
24  
25  
26

## 27 **ETHICS AND DISSEMINATION**

### 28 **Risks and safety**

29  
30 Families of children with autism are a vulnerable group. The risks associated with  
31 participating in this study are however, considered minimal, with no adverse events  
32 anticipated in any participant. For those in the intervention group, there is a slight chance  
33 that the SAFE family therapy sessions could lead to an initial increase in family  
34 disagreements as family members learn how to change the way they solve problems and  
35 talk with one another. However, the purpose of the intervention is ultimately to equip  
36 families with skills to handle these difficulties by learning how to change the way they solve  
37 problems and improve their communication, and the SAFE family therapists will be  
38 available to provide support and will be trained to handle any emerging problems. Should  
39 any issues arise the SAFE family therapists will have access to two consultant clinical  
40 psychologists to provide further support and advice.  
41  
42  
43  
44  
45  
46

47 During the trial the children with autism will remain in the care of the Child Development  
48 Centre or the Autism Spectrum Disorder Assessment Team and will have access to usual  
49 care should any unforeseen circumstances arise. Other members of the family will also  
50 continue to be able to seek care and advice from the GP or any other specialist services  
51 they are concurrently involved with.  
52  
53

### 54 **Monitoring adverse events**

1  
2  
3 The research team have mechanisms in place to report serious adverse events (SAE)  
4 related to mental health. Serious Adverse Events related to mental health may be  
5 volunteered by the participant or discovered by the therapists, research assistants or other  
6 member of the research team during the SAFE family therapy sessions, or as a result of  
7 direct reporting (e.g. by telephone) by a family member, independent clinician or other  
8 informant. Serious adverse events will be recorded from the time of consent until the date  
9 the participant completes the follow-up or withdraws from the study.  
10  
11

12  
13 If the CI considers that the SAE is not, or is unlikely to be, associated with the trial, the CTU  
14 will obtain a second assessment of causality from an independent assessor. Any SAE  
15 which in the opinion of either adjudicator is possibly related to the trial will be reported to the  
16 Research Ethics Committee within 15 days of the local research team having become  
17 aware of the event. All SAEs will be followed until either stabilised if chronic conditions or  
18 resolved.  
19  
20

## 21 **Dissemination**

22  
23 If the feasibility study meets progression criteria an important part of our dissemination plan  
24 is to raise awareness of the need for a larger multi-centre trial. We will, therefore, offer  
25 targeted summaries of our findings and presentations to policy makers. The findings will  
26 also be broadly disseminated, but in a manner appropriate to a feasibility study. We plan  
27 national conference presentations and published papers to inform clinicians, academics  
28 and therapists about the possible benefits of SAFE and generate interest in the future trial.  
29 We will make use of our existing connections including the Association for Family Therapy,  
30 the National Autistic Society and the Institute of Family Therapy to reach relevant  
31 audiences. Our qualitative findings will also be published with detailed accounts of the  
32 families' reactions to SAFE and their views on its effectiveness. We will also provide forums  
33 for participating families to share their own experiences of the intervention with wider  
34 audiences through existing networks, groups and events across the UK.  
35  
36  
37  
38  
39

## 40 **Informing potential participants of possible benefits and known risks**

41  
42 The participant information sheets and leaflets will provide potential participants with  
43 information about the possible benefits and risks of taking part in the trial. For example, the  
44 participants will be informed that a potential risk of receiving the SAFE therapy is that the  
45 sessions may evoke difficult emotions and feelings this could lead to family disagreement  
46 as they move towards change. The families will also be informed that benefits of the trial  
47 include the possibility of improved coping skills when faced with challenges and contribution  
48 to finding out if SAFE can progress to a national trial. Participants will be given the  
49 opportunity to discuss risks and benefits with a member of the research team prior to  
50 consenting to participate.  
51  
52  
53  
54

## 55 **Obtaining Informed consent from participants**

1  
2  
3 All participants will receive a leaflet and information sheet prior to consent. There are two  
4 versions of the information sheet, one for adults and one for children. In the leaflet parents  
5 are encouraged to explain the trial to their younger children and some guidance for doing  
6 this is provided. The information sheet states that the participants have the right to withdraw  
7 at any point during the trial and that data collected from them will be confidential. All  
8 participants will have a home-visit prior to consent from a member of the research team and  
9 will be able to ask questions or go through the information verbally. Participants will have  
10 the process of the study explained to them including the estimated time they will have to  
11 wait prior to randomisation and starting the intervention if allocated to that arm.  
12  
13

### 14 15 **Data protection/confidentiality**

16  
17  
18 Participants will be given a unique identification number. The data will be pseudo-  
19 anonymised in the sense that there will be an identification number on the documentation  
20 but otherwise no means of identifying the individual to which the data relates. The research  
21 team will ensure that participants' pseudo-anonymity is maintained on all documents. Data  
22 will be collected and stored in accordance with the current legal and regulatory  
23 documentation. Electronic study records will be stored in a SQL server database, stored on  
24 a restricted access, secure server maintained by Plymouth University. Data will be entered  
25 into the database via a bespoke web-based data entry system encrypted using SSL.  
26 Access to electronic data will be permission based, and at the discretion of the clinical trials  
27 unit data management team.  
28  
29  
30

31  
32 Anonymised paper-based study data will be stored in locked filing cabinets. Copies of study  
33 data retained at the lead study site will be securely stored for the duration of the study prior  
34 to archiving. Video data will be transported via encrypted memory sticks and will be  
35 transferred to a password-protected computer. The clinical trials unit data team will have  
36 access to study data, including identifiable data. Other members of the study team and the  
37 trials unit will have restricted access to pseudo-anonymised study data. Access will be  
38 granted to the Sponsor and host institution on request, to permit study-related monitoring,  
39 audits and inspections.  
40  
41  
42

### 43 **Research governance and the conduct of the trial**

44  
45 The trial will be conducted to protect the human rights and dignity of the participant as  
46 reflected in the Helsinki Declaration. An important factor in protecting the participants is  
47 ongoing consultation with the SAFE Family Consultation Group. A representative of this  
48 group is a member of the research team and is involved in decision-making processes. The  
49 research team including the family consultation group are proactive in minimising  
50 discomfort and risk for participants, respecting their wishes over science and society,  
51 respecting the right to withdraw and the need for families to have access to all relevant  
52 information.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The Chief Investigator will be responsible for the overall conduct of the study, keeping it to  
4 schedule and within budget. Working closely with the CTU she will be the focal contact for  
5 enquiries from both sites. The CTU will manage the study, liaise with sites, monitor  
6 recruitment, work with the Sponsor and report to Trial Management Group (TMG) meetings.  
7 The TMG will meet regularly throughout the feasibility study. A Trial Steering Committee  
8 (TSC) will have an overarching monitoring responsibility. The TSC is expected to meet  
9 three times during the study, but will be additionally convened at the chairman or Chief  
10 Investigator's request.  
11  
12  
13

### 14 15 **Dissemination plans**

16  
17 If the feasibility study demonstrates successful recruitment, data collection and an ability to  
18 deliver the intervention, an important part the dissemination plan is to raise awareness of  
19 the need for a larger multi-centre trial. Targeted summaries of the findings and  
20 presentations will be disseminated to policy makers. The findings will also be broadly  
21 disseminated, but in a manner appropriate to a feasibility study. National conference  
22 presentations and published papers will be prepared to inform clinicians, academics and  
23 therapists about our feasibility results and generate interest in the future trial. Existing  
24 connections including the Association for Family Therapy, the National Autistic Society and  
25 the Institute of Family Therapy will be utilised to reach relevant audiences. The qualitative  
26 findings will also be published with detailed accounts of the families' reactions to SAFE and  
27 their views on its usefulness. A summary of study results in plain English will be available  
28 on the Peninsula Clinical Trials website.  
29  
30  
31  
32  
33  
34  
35

### 36 **Clinical trials authorisation and ethical approval**

37  
38 Clinical trials authorisation is not required. The study has appropriate Research Ethics  
39 Committee (REC) approval from the South West-Exeter Research Ethics Committee (Ref:  
40 17/SW/0192) and approval from the Health Research Authority (HRA). The trial will be  
41 conducted in accordance with the protocol, the principles of the Declaration of Helsinki and  
42 ICH GCP. Any amendments of the protocol will be submitted to the Sponsor, HRA and REC  
43 for approval.  
44  
45

### 46 **Trial sponsorship**

47  
48 The trial is sponsored by University Hospitals Plymouth NHS Trust.  
49  
50

### 51 **Trial Steering Committee**

52  
53 The Trial Steering Committee will include an independent chair and at two other  
54 independent members, along with the lead investigator and the other study collaborators  
55 including a parent representative. They will meet once a year.  
56  
57  
58  
59  
60

## REFERENCES

1. National Autistic Society, 'Autism Facts and History', accessed 22 March 2018
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, Washington, DC 2013.
3. Sasson NJ, Lam KSL, Parlier M, et al. Autism and the broad autism phenotype: familial patterns and intergenerational transmission. *J Neurodev Disord* 2013; 5:11-18.
4. Dykens EM, Fisher MH, Taylor JL, et al. Reducing Distress in Mothers of Children with Autism and Other Disabilities: A Randomized Trial. *Pediatrics* 2014; 2013-3164.
5. Hallett V, Ronald A, Colvert, E, et al. Exploring anxiety symptoms in a large-scale twin study of children with autism spectrum disorders, their co-twins and controls. *Journal of Child Psychology and Psychiatry* 2013;54:1176-1185.
6. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. *J Autism Dev Disord* 2006;36: 863-870.
7. Kim JA, Szatmari P, Bryson SE, et al. The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. *Autism* 2000; 4:117-132.
8. Howlin P. Interventions for people with autism: recent advances. *Adv Psychiatr Treat* 1997;3: 94-102.
9. Mazefsky CA, Folstein SE, Lainhart JE. Overrepresentation of Mood and Anxiety Disorders in Adults with Autism and Their First Degree Relatives: What Does it Mean? *Autism Res* 2008;1:193-197.
10. Daniels JL, Forssen U, Hultman M, et al. Parental Psychiatric Disorders Associated With Autism Spectrum Disorders in the Offspring. *Pediatrics* 2008;121:1357-1162.
11. Siklos S, Kerns KA. Assessing Need for Social Support in Parents of Children with Autism and Down Syndrome. *J Autism Dev Disord* 2008;36:921-933.
12. Markoulakis R, Fletcher P, Bryden P. Seeing the glass half full: benefits to the lived experiences of female primary caregivers of children with autism. *Clin Nurse Spec*. 2012;26(1):48-56.

- 1  
2  
3 13. Potter CA. 'I accept my son for who he is – he has incredible character and personality':  
4 fathers' positive experiences of parenting children with autism. *Disabil Soc*,  
5 2016;31(7):948-965.  
6
- 7  
8 14. Myers BJ, Mackintosh VH, Goin-Kochel RP. "My greatest joy and my greatest heart  
9 ache:" Parents' own words on how having a child in the autism spectrum has  
10 affected their lives and their families' lives. *Res Autism Spectr Disord*. 2009;3(3):670-  
11 684.  
12
- 13 15. Zhang W, Yan TT, Barriball KL, While AE, Liu XH. Post-traumatic growth in mothers of  
14 children with autism: a phenomenological study. *Autism*. 2015;19(1):29-37.  
15
- 16  
17 16. Altieri MJ, von Kluge S. Searching for acceptance: challenges encountered while  
18 raising a child with autism. *J Intellect Dev Disabil*. 2009;34(2):142-152.  
19
- 20  
21 17. McCrone P, Dhanasiri S, Patel A, et al. The cost of mental health care in England to  
22 2026. Executive Summary, London: The King's Fund. 2008  
23
- 24  
25 18. Buescher AVS, Cidav Z, Knapp M, et al. Costs of Autism Spectrum Disorders in the  
26 United Kingdom and the United States. *JAMA Pediatr* 2014;e1-e8.  
27
- 28  
29 19. Osborne LA, McHugh L, Saunders J, et al. Parenting Stress Reduces the Effectiveness  
30 of Early Teaching Interventions for Autistic Spectrum Disorders. *J Autism Dev*  
31 *Disord* 2008;38:1092-1103.  
32
- 33  
34 20. Pisula E. Parenting Stress in Mothers and Fathers of Children with Autism Spectrum  
35 Disorders, A Comprehensive Book on Autism Spectrum Disorders, Dr. Mohammad-  
36 Reza Mohammadi (Ed.) 2011. Available from: [http://www.intechopen.com/books/a-](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
37 [comprehensive- bookon- autism-spectrum-disorders/parenting-stress-in-mothers-](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
38 [and-fathers-of-children-with-autismspectrum-disorders](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
39
- 40  
41 21. Bolton PF, Pickles A, Murphy M, et al. Autism, affective and other psychiatric disorders:  
42 patterns of familial aggregation. *Psychological Medicine* 1998;28: 385-395.  
43
- 44  
45 22. Demir T, Dogangun B, Karacetin G, et al. Psychiatric Disorders and Symptoms in  
46 Mothers of Children with Autistic Disorder. *Neurol Psychiatry Brain Res* 2008;15:1-5.  
47
- 48  
49 23. Piven J, Palmer P. Psychiatric disorder and the broad autism phenotype: evidence from  
50 a family study of multiple-incidence autism families. *Am J Psychiatry* 1999;156:557-  
51 563.  
52
- 53  
54 24. Nikmat AW, Ahmad M, Oon NL, et al. Stress and psychological wellbeing among  
55 parents of children with autism spectrum disorder. *ASEAN Journal of Psychiatry*  
56 2008;9:65-72.  
57  
58  
59

- 1  
2  
3 25. Roberts AL, Koenen KC, Lyall K, Ascherio A, Weisskopf MG. Women's posttraumatic  
4 stress symptoms and autism spectrum disorder in their children. *Res Autism Spectr*  
5 *Disord* 2014;8(6):608-616.  
6
- 7  
8 26. Roberts AL, Lyall K, Rich-Edwards JW, Ascherio A, Weisskopf MG. Maternal exposure  
9 to intimate partner abuse before birth is associated with autism spectrum disorder in  
10 offspring. *Autism* 2016;20(1):26-36.  
11
- 12  
13 27. Konstantareas MK. Autistic, learning disabled and delayed children's impact on their  
14 parents. *Can J Behav Sci* 1991;23:358-375.  
15
- 16  
17 28. Murphy M, Bolton PF, Pickles A, et al. Personality traits of the relatives of autistic  
18 probands. *Psychol Med* 2000;30:1411-1424.  
19
- 20  
21 29. Blackledge JT, Hayes SC. Using Acceptance and Commitment Training in the Support  
22 of Parents of Children Diagnosed with Autism. *Child & Family Behavior Therapy*,  
23 2006;28:1-18.  
24
- 25  
26 30. NICE guidelines [CG170] [https://www.nice.org.uk/guidance/cg170/chapter/patient-](https://www.nice.org.uk/guidance/cg170/chapter/patient-centred-care)  
27 [centred-care](https://www.nice.org.uk/guidance/cg170/chapter/patient-centred-care)  
28
- 29  
30 31. NICE guidelines [CG128] <https://www.nice.org.uk/guidance/cg128>  
31
- 32  
33 32. Munroe E. The Munroe Review of Child protection: Final report, Dept. of Education, HM  
34 Stationary Office, UK 2011.  
35
- 36  
37 33. Goodman S, Trowler I. Social work re-claimed: Innovative frameworks for child and  
38 social work Practice. London: Jessica Kingsley 2012.  
39
- 40  
41 34. NHS England. Future in Mind: promoting, protecting and improving our children and  
42 young people's mental health and wellbeing. Dept of Health Publication Gateway  
43 Ref. No 02939, 2015.  
44
- 45  
46 35. IAPT | CYP IAPT Children and Young People's Project. (n.d.). Retrieved January 5,  
47 2015, from <http://www.iapt.nhs.uk/cyp-iapt/>  
48
- 49  
50 36. Bromley J, Hare DJ, Davison K. et al. Mothers supporting children with autistic  
51 spectrum disorders: Social support, mental health status and satisfaction with  
52 services. *Autism* 2004;8:409-423.  
53
- 54  
55 37. Stratton P. Report On The Evidence Base Of Systemic Family Therapy. *Association for*  
56 *Family Therapy* 2005.  
57
- 58  
59 38. Dallos R, Draper R. (4th Edn) An Introduction to Family Therapy. Maidenhead: Open  
60 Univ. Press/McGraw Hill 2015.

- 1  
2  
3 39. Monteiro M. Family Therapy and the Autism Spectrum: Autism Conversations in  
4 Narrative Practice. London: Routledge 2016.  
5  
6  
7 40. Estrada AU, Pinsof WF. The effectiveness of family therapies for selected behavioural  
8 disorders of childhood. *J Marital Fam Ther* 1995;21: 403-424.  
9  
10 41. Pellicano E, Dinsmore A, Charman T. What should autism research focus upon?  
11 Community views and priorities from the United Kingdom. *Autism, Special Issue*  
12 *Article* 2014:1-15.  
13  
14  
15 42. Wallace S, Parr J, Hardy, A. One in a hundred: Putting families at the heart of autism  
16 research. London: Autistica 2013.  
17  
18 43. Stratton P, Bland J, Janes E, et al. Developing an indicator of family function and a  
19 practicable outcome measure for systemic family and couple therapy: the SCORE.  
20 *Journal of Family Therapy* 2010;32:232-258.  
21  
22  
23 44. Stratton P, Lask J, Bland J, Nowotny E, Evans C, Singh R, Janes E, Peppiatt A.  
24 Detecting therapeutic improvement early in therapy: validation of the SCORE-15  
25 index of family functioning and change. *J Fam Ther* 2014;36:3-19.  
26  
27 45. SHIFT Self-Harm Intervention, Family Therapy: a randomised controlled trial of family  
28 therapy vs. treatment as usual for young people seen after second or subsequent  
29 episodes of self harm. Protocol Grant Number: 470772 HTA Reference Number:  
30 07/33/01, 2015.  
31  
32  
33 46. SCORE-15 [Internet ] Association for Family Therapy [www.aft.org.uk](http://www.aft.org.uk). [cited 2018 Sept  
34 17] Available from:  
35 [http://www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/SCORE%20info/SCORE-](http://www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/SCORE%20info/SCORE-15%20102013.pdf)  
36 [15%20102013.pdf](http://www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/SCORE%20info/SCORE-15%20102013.pdf)  
37  
38  
39 47. Kroenke K, Spitzer RL, Williams JBW, Lowe B. The Patient Health Questionnaire  
40 Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp*  
41 *Psychiatry* 2010;32:345-359.  
42  
43  
44 48. Spitzer R L, Kroenke K, Williams JBW. The Patient Health Questionnaire Primary Care  
45 Study Group. Validation and utility of a self-report version of PRIME-MD: the PHQ  
46 Primary Care Study. *JAMA*, 282, 1999:1737-1744.  
47  
48  
49 49. Blazey L. Coding of Attachment-Related Parenting for use with children with Autism  
50 (CARP-A) [dissertation]. Manchester: Manchester University, 2007.  
51  
52  
53 50. Holt CE. Child-caregiver Play and Attachment in Pre-school Autism: A Longitudinal  
54 Investigation [thesis]. Manchester: University of Manchester, 2011.  
55  
56 51. Moss E, Bureau J, Cyr C, et al. Correlates of attachment at age 3 Construct validity of  
57 the Preschool Attachment Classification System. *Dev. Psychol* 2004;40:323-334.  
58  
59

- 1  
2  
3 52. Achenbach TM, Rescorla LA. Manual for the ASEBA School-Age Forms and Profiles:  
4 Child Behaviour Checklist for Ages 6-18. Burlington, VT: University of Vermont,  
5 Research Center for Children, Youth, & Families. 2001.  
6  
7 53. Fonagy P, Luyten P, Moulton-Perkins A, et al. Development and validation of a self-  
8 report measure of mentalizing: The Reflective Functioning Questionnaire. PLOS  
9 ONE. 2016;11(7):e0158678.  
10  
11 54. Solomon J, George C. (Eds.) Disorganised Attachment and Caregiving. Guilford: New  
12 York; 2011.  
13  
14 55. Huth-Bocks AC, Guyon-Harris K, Calvert M, Scott S, Ahlfs-Dunn S. The Caregiving  
15 Helplessness Questionnaire: Evidence for validity and utility with mothers of infants.  
16 *Infant Ment Health J*. 2016;37:208-221.  
17  
18 56. Ogletree BT, Morrow-Odom KL, Wrestling D. Understanding the brain-behaviour  
19 relationship in persons with ASD: Implications for PECS as a treatment choice. *Dev*  
20 *Neurorehabil* 2015;18(2): 88-96.  
21  
22 57. Buron KD, Wolfberg P. Learners on the autism spectrum: Preparing highly qualified  
23 educators (pp. 114–137). AAPC Publishing: Shawnee; 2008.  
24  
25 58. Grandin T, Scariano MM. (1986). *Emergence: Labeled autistic*. New York, NY: Warner  
26 Books 1986.  
27  
28 59. Slade A, Aber JL, Bresgi I, Berger B, Kaplan M. The parent development interview,  
29 revised. Unpublished protocol. The City University of New York 2004.  
30  
31 60. CONSORT extension for Randomized Pilot and Feasibility Trials ([http://www.consort-](http://www.consort-statement.org/randomised-pilot-and-feasibilitytrials)  
32 [statement.org/randomised-pilot-and-feasibilitytrials](http://www.consort-statement.org/randomised-pilot-and-feasibilitytrials)).  
33  
34 61. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*.  
35 2006;3:77-101.  
36  
37 62. Green J, Thorogood N. *Qualitative Health Methods for health Research*. London: Sage  
38 Publications; 2004.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **AUTHORS' CONTRIBUTIONS:** RM, JV and HH were responsible for the overall  
50 development of the protocol. RM, HH, RD, CM, PE, AB, TV and the Family Consultation  
51 Group were involved in the conception and production of the study and the development of  
52 the initial protocol. PE and AB provided methodological expertise and advice on quantitative  
53 analysis PE provided statistical expertise. RD was the lead researcher on design of the  
54 intervention and the qualitative component. TV, with the support of the Family Consultation  
55 Group, and CM advised on design and ethics, particularly from the participant perspective.  
56  
57  
58

1  
2  
3 All authors made substantial contributions to drafting, revision and approval of the  
4 document.  
5

6 **ACKNOWLEDGEMENTS:** The Authors would like to thank the SAFE Family Consultation  
7 Group for their ongoing input and expertise. They would also like to thank James Cook,  
8 Mary Hosken, Dr Ben Whalley, Dr Antonieta Medina-Lara and Professor Julian Archer for  
9 their help in developing and conducting this study.  
10  
11

12  
13 **FUNDING STATEMENT:** This work was supported by the National Institute for Health  
14 Research (NIHR) grant number: PB-PG-0815-20058  
15


16  
17 **COMPETING INTERESTS STATEMENT:** Contributors are co-applicants or employed  
18 research staff on the SAFE project, which receives funds from both NIHR and Autistica.  
19 Professor Rudi Dallos holds joint Intellectual Property rights for the SAFE intervention with  
20 The University of Plymouth. No other issues were raised with regard to competing interests.  
21  
22

23 **PROVENANCE AND PEER REVIEW:** Not commissioned; externally peer reviewed.  
24

25 **DATA SHARING STATEMENT:** Further details of the study protocol can be requested  
26 from the corresponding author.  
27  
28

29  
30  
31  
32  
33  
34 Legend for Figure 1.

35  
36 Figure 1. SAFE study schema  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60







SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Front page
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Front page
	2b	All items from the World Health Organization Trial Registration Data Set	Front page, 6, 9
Protocol version	3	Date and version identifier	Front page
Funding	4	Sources and types of financial, material, and other support	34
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	6
	5b	Name and contact information for the trial sponsor	6
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	5
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	30 - 32

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47**Introduction**

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	10 -11
	6b	Explanation for choice of comparators	29 - 30
Objectives	7	Specific objectives or hypotheses	11 - 12
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	12

**Methods: Participants, interventions, and outcomes**

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	16
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	16
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	21 - 22
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	21
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	21, 30
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	22
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14 - 15
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	19

1  
2  
3 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 29 - 30  
4 clinical and statistical assumptions supporting any sample size calculations

5  
6 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 20  
7

8 **Methods: Assignment of interventions (for controlled trials)**  
9

10 Allocation:

11 Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 29 - 30  
12 factors for stratification. To reduce predictability of a random sequence, details of any planned restriction  
13 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants  
14 or assign interventions  
15

16  
17 Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 19 - 20  
18 opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned  
19  
20

21 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 20  
22 interventions  
23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 20 - 21  
25 assessors, data analysts), and how  
26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's 20 - 21  
28 allocated intervention during the trial  
29  
30

31 **Methods: Data collection, management, and analysis**  
32

33 Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 27 - 29  
34 processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of  
35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.  
36 Reference to where data collection forms can be found, if not in the protocol  
37

38 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 24 - 25  
39 collected for participants who discontinue or deviate from intervention protocols  
40  
41  
42  
43  
44

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	28
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	29 - 30
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	25 - 26
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	29 - 30
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	31 - TSC performing DMC role.
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	33
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	26 - 27
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	30 - 31
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	32 - 33
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	32



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	18
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	23
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	28 - 29
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	29
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	33
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	33 - 34
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40

# BMJ Open

## **SAFE, a new therapeutic intervention for families of children with autism: study protocol for a feasibility randomised controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025006.R2
Article Type:	Protocol
Date Submitted by the Author:	07-Mar-2019
Complete List of Authors:	McKenzie, Rebecca; University of Plymouth, Institute of Education Dallos, Rudi; Department of Clinical Psychology, University of Plymouth Stedmon, Jacqui; The University of Plymouth, Clinical Psychology Hancocks, Helen Vickery, Patricia; Plymouth University, Peninsula Clinical Trials Unit Ewings, Paul; Research Design Service, Research Office Barton, Andy; South West Research Design Service Vassallo, Tara Myhill, Craig
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Public health, Pathology, Research methods
Keywords:	autism, family therapy, intervention, feasibility

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **SAFE, a new therapeutic intervention for families of children with autism: study**  
5  
6 **protocol for a feasibility randomised controlled trial**  
7  
8  
9  
10

11 Rebecca McKenzie<sup>1</sup>, Rudi Dallos<sup>1</sup>, Jacqui Stedmon<sup>1</sup>, Helen Hancocks<sup>2</sup>, Jane Vickery<sup>2</sup>, Paul  
12 Ewings<sup>3</sup>, Andy Barton<sup>3</sup>, Tara Vassallo<sup>1</sup>, Craig Myhill<sup>1</sup>  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Author affiliations  
24

- 25 1. Plymouth University. Plymouth UK
- 26 2. Peninsula Clinical Trials Unit, Plymouth University. Plymouth UK
- 27 3. NIHR Research Design Service. South West. UK
- 28
- 29
- 30

31 Correspondence to: Dr Rebecca McKenzie [rebecca.mckenzie@plymouth.ac.uk](mailto:rebecca.mckenzie@plymouth.ac.uk)  
32  
33  
34  
35  
36  
37

38 Key words: Family Therapy, autism, intervention, feasibility, mental health  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Word count: 5903 excluding title page, abstract and references

## ABSTRACT

**Introduction:** Incidence of autistic traits, mental health problems, stress and poor coping is high among family members of children with autism. These problems are coupled with challenging behaviour among children with autism. Current treatment for these families is disjointed and costly. The need for whole family support is supported by NICE recommendations, developments regarding children's service provision, research and requests by families of children with autism. Despite evidence that family therapies can provide benefits to these families, its efficacy has not been subject to a randomised controlled trial. SAFE is a new family therapy intervention designed specifically for families of children with autism. We aim to establish the feasibility of running a fully powered randomised controlled trial to evaluate SAFE.

**Methods and analysis:** Families of children with autism aged 3-16 years will be invited to participate. Consenting participants will be randomised 2:1 to either SAFE + support as usual or support as usual alone. The proposed primary outcome measure for the main trial will be the Systemic CORE 15. Participants will also complete proposed secondary outcome measures, indexing changes in child behaviour, child-parent attachment, anxiety, and depression. Generic health economic outcome measures (EQ-5D-5L and CHU-9D) will also provide data on the feasibility of cost effectiveness analysis. Questionnaires will be completed at baseline and 32 weeks post allocation. Data on ability to identify, recruit, randomise, retain and collect data from families, acceptability of outcome measures, adherence of therapists and families to the intervention, appropriateness of resource use questionnaires and effectiveness of training will be collected for feasibility analysis. Qualitative data will also explore acceptability of SAFE and reasons for declining and withdrawing from the study.

**Ethics and dissemination:** The current trial protocol received ethical approval from the South West-Exeter Research Ethics Committee (Ref: 17/SW/0192). The findings of the trial



1  
2  
3 will be disseminated in collaboration with our Family Consultation Group and other partners.  
4  
5 Findings will be shared locally, nationally and internationally through events, conferences  
6  
7 and published papers.  
8  
9

10 **Trial registration number:** ISCTRN83964946 IRAS 213527  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

## 35 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 36  
37  
38 • The study addresses a gap in the available research data, and will produce  
39 important feasibility information to inform a fully powered randomised controlled trial.  
40  
41
- 42 • The study explores the feasibility of using measures of family function and a range of  
43 mental health measures.  
44  
45
- 46 • Quantitative feasibility data are complemented by qualitative focus groups and  
47 interviews.  
48  
49
- 50 • The study explores the feasibility of economic analysis measures in a population,  
51 which includes adults and their children with developmental disorders.  
52  
53
- 54 • The participants are recruited from two NHS Trusts in adjacent counties in the South  
55 West of England, leading to potential bias. A future randomised controlled trial will  
56 extend to centres across the UK including Scotland and Wales.  
57  
58  
59  
60

## INTRODUCTION

More than 1% of the UK population has a diagnosis of autism [1]. Families of children with autism present complex needs. Children with autism have impairments in social interaction, communication, and behavioural flexibility [2]. Autism is widely accepted to have a genetic component and the Broad Autism Phenotype is disproportionately represented among family members [3]. Mental health problems are experienced by more than 70% of individuals with autism and more than 50% of their parents [4,5]. Individuals with autism suffer from high levels of anxiety and depression compared to those with other developmental conditions [6,7,8]. Families of children with autism have higher rates of depression, anxiety, and social phobia, than families with typically developing children, or children with other developmental disorders [9]. Parents of children with autism are more likely to be hospitalised for mental disorders than parents of typically developing children [10]; and mothers of children with autism are reported to have higher unmet needs, more difficulties coping, and lower satisfaction with service interactions than mothers of children with other disabilities [11]. Aside from these reported difficulties, families of children with autism can have positive family experiences, sense of wellbeing [12] and positive perceptions of their children [13]. Despite challenges, autism can be seen as enhancing family experience and some parents recognise that parenting a child with autism has added joy to their lives [14], made them more appreciative [15], more patient and compassionate [16].

As families of children with autism often exhibit psychological morbidities alongside autism, costs of services to treat these problems are high [17,18]. Furthermore, untreated or unresponsive mental health problems impose societal costs making it hard for parents to interact effectively with services [19], potentially worsening outcomes for children and exacerbating the substantial economic burden of autism [18].

1  
2  
3  
4 Explanations for high levels of affective disorders in these families include: stress  
5 associated with the condition of autism, genetic factors, and intergenerational family  
6 dynamics. Parenting children with autism involves stresses associated with challenging  
7 behaviour, lack of Theory of Mind, and atypical attachment behaviour displayed by children  
8 [20]. Parents of children with autism report that a consequent lack of psychological  
9 wellbeing exacerbates maladaptive behaviour in their children [21], which is likely to result  
10 in unhelpful cycles of distress and hopelessness.  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Studies exploring the medical histories of family members indicate, that the onset of  
21 affective disorders may predate the birth of the child [9,22,23] suggesting that mental health  
22 difficulties cannot be wholly accounted for by stress involved in parenting. It seems,  
23 therefore, that these individuals may have been living with psychological distress for a long  
24 period of time. Depression and anxiety among family members have been tentatively linked  
25 to genetic factors independent of the Broad Autism Phenotype [24]. But few studies explore  
26 the intergenerational presence of affective disorder associated with autism [9,23,23].  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Previous research demonstrates that experience of trauma and abuse among women is  
37 associated with elevated risk of autism developing in their subsequent offspring [25,26].  
38 Hence mothers of children with autism are more likely than the general population to be  
39 coping with previous traumatic events. In addition, these families often encounter difficulties  
40 communicating needs to external agencies [27], which may trigger existing tendencies for  
41 negative affect. Families of children with autism can experience positive family life, cope  
42 well with difficulties and enjoy good relationships with their children, but they represent a  
43 high-risk group, for whom treatment is disjointed, costly and inadequate [28,29].  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 A more joined-up approach is required which focuses on autism related need, coping with  
55 challenging behaviour and mental health difficulties by encouraging fundamental reflective  
56 functioning and improving family dynamics. The SAFE study should be placed in the  
57 context of NICE guidelines and recommendations [30,31] as well as developments  
58  
59  
60

1  
2  
3 regarding children's service provision proposed by the Munroe Report [32,33], and the  
4 'Future in Mind' children and young people's mental health report [34]. The SAFE study  
5 also reflects recommendations by other researchers working in the field [35,36]. Families of  
6 children with autism themselves highlight the importance of professionals working  
7 therapeutically with children and the wider family, in contrast to parents of children with  
8 conditions such as Down Syndrome who tend to stress the support needs of their child  
9 within educational and community settings [10].  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 SAFE is a systemic family therapy approach designed by experts to address autism related  
21 needs including mental health difficulties and problematic behaviour. Systemic Family  
22 Therapy is a well-recognized, evidence-based psychotherapeutic approach [37], which is  
23 recommended treatment for conditions such as Conduct Disorder, ADHD and Anorexia  
24 Nervosa [38]. Despite evidence that family therapies can provide benefits to children with  
25 autism and their parents [39,40] its efficacy for treating this condition has not been subject  
26 to a randomised controlled trial. A comprehensive search of clinical trial registries revealed  
27 no on-going trials assessing Systemic Family Therapy as a treatment for autism and  
28 associated mental health problems. This is surprising given guidelines and  
29 recommendations for care; the successful use of family therapies for a range of conditions  
30 and reports documenting key areas of concern for the UK autism community [41,42], which  
31 overwhelmingly show that families of children with autism want interventions which make  
32 real improvements to their daily life and sense of wellbeing. Consequently, the overarching  
33 aim of this study is to establish the feasibility of a definitive randomised controlled trial to  
34 evaluate Systemic Autism-related Family Enabling (SAFE) therapy for families of children  
35 with autism.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## 55 **METHODS AND ANALYSIS**

### 56 **Participants and recruitment**

57  
58  
59  
60

1  
2  
3  
4 Our target population are families of children with autism, who do not have an intellectual  
5 impairment, between the ages of 3 and 16 years. SAFE is designed to have a visual, playful  
6 approach which draws from established principles of family therapy, where therapists and  
7 families work as collaborators to solve problems and effect change. SAFE activities are  
8 adaptable, family led and can be used flexibly according to the needs of the family and the  
9 age of the child. Children gain most from the intervention, however, if they can understand  
10 and communicate their responses to SAFE activities. Pilot data suggest that SAFE will be  
11 most effective and accessible for children who do not have severe symptoms or an  
12 intellectual impairment. Those children who were non-verbal and/or had severe  
13 communication difficulties found it difficult to engage with some activities. For this feasibility  
14 study, therefore, our target population is families of children with autism severity level 1 or 2  
15 with no intellectual impairment. The authors are aware that high severity levels may not in  
16 all cases exclude children from engaging with SAFE and that the relationship between IQ  
17 and severity is complex. These issues will be explored as part of the feasibility outcomes,  
18 namely our ability to recruit eligible families.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 Future plans for SAFE include the development of a sister intervention which has extended  
33 non-verbal elements based on Intensive Interaction and is designed specifically to support  
34 families of children with autism and an intellectual impairment. This feasibility study focuses  
35 on families of children of school-age which fits with the priorities of one of our secondary  
36 sources of funding. Background research exploring diagnostic data for our proposed centres  
37 for the previous two years revealed no children without intellectual impairment diagnosed  
38 before the age of 3 years. This information strongly suggested that we would be unable to  
39 recruit any families with children below the age of 3 years. Consequently, we focused on the  
40 3-16 age group.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Participants will be identified and recruited from two study research sites: University Hospitals  
54 Plymouth NHS Trust (PHNT) Child Development Centre, and Cornwall Partnership NHS  
55 Foundation Trust Autism Spectrum Disorder Assessment Team (ASDAT). The pathways  
56 used to identify and recruit families will vary according to local practice, and the needs of the  
57  
58  
59  
60

1  
2  
3 individual families being approached. Some families will receive a diagnosis during the SAFE  
4 recruitment period, and others will have been diagnosed up to 12 months before the SAFE  
5 study recruitment period starts.  
6  
7  
8

9  
10 Families with a diagnosis during the SAFE recruitment period will be approached by the  
11 diagnosing paediatrician, who will perform an initial eligibility check, invite the families to  
12 find out more and, if interested, refer the family to a member of the local SAFE study team.  
13 Families with a diagnosis before the SAFE study recruitment period will be identified as  
14 potentially eligible from clinic records by a suitably qualified member of the clinical team at  
15 each centre. Clinical staff in our centres and the surrounding areas are responsible for  
16 diagnosis of the children within our participating families. If the child is recruited from a  
17 diagnostic centre the clinical staff also assess eligibility. The severity levels of the children  
18 and their intellectual ability are assessed on the autism pathways in Plymouth and Cornwall  
19 by a multi-disciplinary clinical team including educational and clinical psychologists, speech  
20 and language therapists and paediatricians. Assessment on the pathways occurs over a  
21 period of several months. This includes measures of IQ based on the Wechsler Intelligence  
22 Scale for Children WISC-V [43] and measures of intellectual functioning based on the  
23 British Ability Scales BAS3 [44] as well as observations and detailed reports from the  
24 schools or nursery settings and the family.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 All potential participant families will receive a participant information leaflet including an  
42 invitation to take part. All interested families will be able to speak to a member of the study  
43 team to discuss the study and have any questions answered. The participant information  
44 leaflet will contain information about the study in plain English. Parents will be asked to  
45 explain the information to younger children in a way that is appropriate for their child and  
46 suggestions for how to do this will be contained in the leaflet. A home visit will be arranged  
47 by a member of the study team for those families who express interest in participating. During  
48 the visit, a research assistant will provide the families with more detailed participant  
49 information and seek consent.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Community pathway

Participants that have received either a new diagnosis, or a diagnosis within the last 12 months will also be approached through community groups, using a recruitment poster, invitation letter, reply slip, participant information leaflet, and freepost envelope. These participants will be contacted by a member of the research team by telephone at which time they will discuss the study and answer questions. The families will also be asked to consent to providing the original NHS diagnosis letter, which will be used by the research staff to determine eligibility to participate in the study, and legal guardianship at the first home visit.

## Inclusion criteria

- Family includes child with ASD, aged 3-16 years
- Diagnosis of autism spectrum disorder, severity level 1 or 2
- Diagnosed within 12 months of consenting to the study
- If other diagnoses are present, ASD must be primary diagnosis
- Family are willing to comply with study requirements

## Exclusion criteria

- Children with ASD severity level 3
- Children with ASD and intellectual impairment\*
- Serious concomitant illness in child or family, or other circumstances such that they are unable to comply with study requirements
- Families who may be a risk to safety of research staff (This will be assessed by the clinical and research staff on the basis of clinical records, diagnosis letter and contact prior to the first home visit).
- Insufficient English language or capacity for parent/child to consent/assent to the study.

\* Intellectual impairment will be identified by the clinical staff on the basis of pathway assessments described above including the WISC-V and the BAS3. Impairment will be

1  
2  
3  
4 deemed present on the basis of any of the following criteria:

- 5 • The child has a comorbid diagnosis of intellectual disability
- 6 • Diagnosis specifies "with accompanying intellectual impairment"
- 7 • The child has been identified as requiring very substantial support (severity level 3)
- 8 according to DSM-5 criteria for ASD
- 9 • The child is being educated in a special school for children with intellectual
- 10 disabilities
- 11 • The child has an IQ of 70 or below
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22

### 23 **Study design**

24  
25 This is a randomised, controlled, multi-centred feasibility study including children with  
26 autism and their families (the Study Schema appears in Figure 1.) A total of 36 families will  
27 be recruited in four cohorts and each cohort will be randomised in a 2:1 ratio to receive  
28 support as usually employed (SUE) plus a programme of Systemic Autism-related Family  
29 Enabling (SAFE) therapy, or SUE alone, for a period of 16 weeks. Advantages of 2:1  
30 allocation include:  
31  
32  
33  
34  
35  
36  
37  
38

- 39 • Increased appeal for patients deciding whether to consent to randomisation.
- 40 • Increased ability to test training of therapists, and ability to deliver high-fidelity
- 41 treatment.
- 42 • Minimal reduction in statistical power for between-groups comparisons in a full-scale
- 43 evaluation.
- 44 • Increased ability to recruit required number of families within an area before
- 45 randomising; which will be closer to the figure needed if and when the intervention is
- 46 implemented.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55

56 Outcome assessors will be blinded to allocation. All participants will complete outcome  
57 measures at baseline and again at 32 weeks post-allocation via a face-to-face visit, hence  
58  
59  
60



1  
2  
3  
4 each family will participate in the SAFE study for approximately eight months. An  
5  
6 embedded qualitative study will collect information about the feasibility and acceptability of  
7  
8 the intervention and the study itself. Qualitative data will be collected at a Family Feedback  
9  
10 Day after the 32 week post-allocation visits have been completed. The end date for the trial  
11  
12 will be the date on which the last family completes the Family Feedback Day.  
13  
14

## 15 Outcome measures

### 16 Feasibility outcome measures:

- 17 • Ability to identify, recruit and randomise eligible families.
- 18 • Acceptability of proposed outcome measures and follow-up schedule to participants,  
19 and whether targets for loss to follow-up are achievable.
- 20 • Adherence of therapists and families to the intervention.
- 21 • Ability to gather quantitative data on outcomes
- 22 • Appropriateness of resource use questionnaires and preference-based instruments  
23 for this population
- 24 • Effectiveness and scalability of training arrangements

### 25 Clinical outcome measures:

- 26 • Scores on the proposed primary outcome measure, the Systemic CORE 15  
27 (SCORE) [45]. This is a 15 item paper-based survey, which has been shown to have  
28 good internal reliability (Cronbach's  $\alpha = .89$ ) [46] and to be a valid index of family  
29 functioning, taking approximately 20 minutes to complete. The SCORE is the primary  
30 measure of family functioning employed in CYP (Children and Young People's)  
31 Improving Access to Psychological Therapies national programme, and is the gold  
32 standard for assessing the impact of family therapy on quality of life in the UK [47].  
33 Every able family member will be asked to complete the SCORE, and the same  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 family members should complete the SCORE at baseline and 32 weeks. The  
5 SCORE-15 is freely available online [48].  
6  
7  
8

- 9  
10 • Scores on the proposed secondary outcome measures, which index changes in child  
11 behaviour, child-parent attachment, anxiety, and depression.  
12  
13     ○ Patient Health Questionnaire – Somatic Anxiety Depressive Symptoms (PHQ-  
14 SADS). This comprises the PHQ-9 (estimated internal reliability Cronbach's  $\alpha$   
15 = .86-.89) [49] measuring depression and the GAD-7 (estimated internal  
16 reliability  $\alpha$  =.92 [49] measuring anxiety [50].  
17  
18     ○ Adapted mutuality sub-scale of the Coding of Attachment-Related Parenting  
19 for use with children with Autism - CARP-A [51]. The CARP-A is a validated  
20 observational measure of a child with autism's attachment behaviour towards  
21 their carer The CARP-A Mutuality subscale is reported as having inter-rater  
22 reliability of .74 [52].  
23  
24     ○ The Child Behaviour Checklist (CBCL) [53]. This is a 30-item paper-based  
25 survey, which detects emotional and behavioural problems. Reasonable  
26 internal reliability is reported for each of three scales, given that some scales  
27 only have 4 items: 1. Competence scales (Cronbach's  $\alpha$  = .63-.79) 2.  
28 Problems scales (Cronbach's  $\alpha$  = .78-.97) and 3. DSM orientated scales  
29 (Cronbach's  $\alpha$  = .72-.91) [54].  
30  
31     ○ The Reflective Functioning Questionnaire (RFQ) [53] measures ability to  
32 understand own and others' mental states (Test-retest reliability coefficients  
33 are reported as 0.84) [55].  
34  
35     ○ Caregiving Helplessness Questionnaire [56] (CGHQ). This is a 26-item  
36 questionnaire designed to assess aspects of disorganised caregiving. The  
37 CGHQ includes three subscales with reasonable internal reliability given the  
38 number of items: 1. Mother Helpless ( $\alpha$  = .86) includes 7 items, 2. Mother-  
39 Child Frightened ( $\alpha$  = .66) includes 6 items, 3. Child Caregiving ( $\alpha$  = .64)  
40 includes 6 items [57].  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Scores on generic health economic outcome measures will also provide data on the feasibility of cost effectiveness analysis:
  - EuroQol 5 dimensions (EQ-5D-5L). This is a standardised generic instrument for measuring health outcome.
  - Child Health Utility 9 Dimensions (CHU-9D). The CHU-9D is a paediatric generic preference based measure of health related quality of life.
  - Resource Use Questionnaire (RUQ). A paper-based questionnaire completed by parent about his/her child's use of health care and social resources. The RUQ is designed to identify the NHS and Social Care resource use for the economic evaluation. It includes items to establish number and type of health resources being used, such as number of GP visits or number of days in hospital. Resource Use Questionnaire completion will be matched with medical records for a subgroup of families, which will help to develop strategies to minimise missing data in the future definitive trial.
  
- Qualitative outcomes:
  - Acceptability of SAFE and the trial process for participants and therapists
  - Reasons for declining and withdrawing from the study

The qualitative component will employ focus groups and interviews to investigate four key aspects of the study experience: families' experiences of the study (including intervention and potential harm of the intervention), therapists' experiences of the intervention, reasons for eligible families declining, and reasons for families withdrawing from the study. After the 32-week assessments have been completed, Families will be given details of the qualitative focus groups and invited to attend a family feedback day if they wish to do so. The family feedback day will involve several separate focus group sessions organised to take place over the period of a morning or an afternoon at a local venue for each centre including focus groups aimed specifically at parents and at children. The families will be told at the start of

1  
2  
3  
4 the day that they are not obliged to respond to any question or prompt if they do not wish to  
5 and that the format of the day will be open discussion with other families in response to  
6 questions presented on a screen. They will then be invited to respond to a presented topic  
7 guide exploring the four key areas stated above through discussion with each other.  
8  
9  
10  
11  
12  
13

14 Place Figure 1. Here  
15  
16  
17  
18  
19

## 20 The Intervention

21  
22 SAFE is a manualised intensive programme of systemic family therapy designed to treat  
23 maladaptive autistic symptoms and mental health related difficulties encountered by  
24 families of children with autism. SAFE provides an array of therapeutic activities based on  
25 Attachment Theory, established systemic practice and the known visual processing  
26 preferences of people with autism [For example, 58,59,60]. SAFE is best seen as a toolkit  
27 with a variety of activities which can be applied to family therapy flexibly. For example, a  
28 very young child will engage with activities in a different way to teenagers. Activities include  
29 visual tasks, drawing, modelling, role-play and tracking circular patterns. Sessions are led  
30 by family need and the therapists and family work collaboratively, often in a playful way,  
31 utilising family resources, therapist expertise and the tools that SAFE provides. SAFE  
32 draws heavily from well-documented active and playful approaches in Family Therapy  
33 practice and literature [61].  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Each therapy session will include two therapists with a minimum of intermediate family  
49 therapy level of qualification and four days training in SAFE principles. Prior to the therapy  
50 sessions parents allocated to SAFE will complete an adapted version of the Parent  
51 Development Interview [59], which will provide therapists with background information on  
52 family experience. The reflective functioning questions of this interview will also be revisited  
53 as an opportunity to discuss change at the 24-week follow up. Between weeks 1 and 16,  
54  
55  
56  
57  
58  
59  
60

families allocated to the SAFE intervention will attend five 3-hour SAFE therapy sessions. Sessions 1 and 5 are multi-family sessions and will take place in a community setting. Sessions 2, 3 and 4 are for individual families and will take place in a community venue or the family home. The therapists will facilitate sessions which will be video recorded, as is usual practice for therapy sessions. The videotapes will be used by the therapists in supervision sessions and preparation for subsequent sessions.

Following completion of the therapy programme, families will attend a group follow-up session at 24 weeks post-allocation. Families will discuss any changes they have encountered focusing on their ability to be reflective about challenges faced and solutions tried. Trained support workers from local voluntary groups will attend this follow-up session and will be invited to give the families information about continued support for families of children with autism through existing networks.

Each session will include the following assessments for families to complete:

1. Client Satisfaction Questionnaire (CSQ-8)
2. The Helpful Aspects of Therapy Questionnaire (HAT)
3. A Between Session Activity (BSA) homework activity Families will be encouraged to complete a pro-forma with key elements of the intervention as prompts for families to track strengths and difficulties in response to SAFE ideas. Completion of the BSA will be recorded.

At the end of each session the therapists will also complete a training checklist and questionnaire to monitor protocol adherence.

### **Support as usually employed**

Families will typically be offered a post-diagnosis follow-up appointment with the diagnosing

1  
2  
3  
4 paediatrician. Parents of children whose symptoms are not severe may be directed to local  
5 authority parenting classes. Classes such as 'Timeout for Autism' (Cornwall and the Isles of  
6 Scilly) and 'Understanding Autism' (Plymouth) focus on the features of Autism Spectrum  
7 Disorder, instructional parenting techniques and issues associated with education. Psycho-  
8 education may also be offered, with families being directed to relevant resources for e.g. The  
9 National Autism Society, Gateway ASD, and the NHS Child and Adolescent Mental Health  
10 Services (CAMHS). For families where a member is experiencing depression or anxiety,  
11 treatment varies and is not linked to autism-related care. Initial referral is often through the  
12 GP. Patients may receive Cognitive Behavioural Therapy as part of the Improved Access for  
13 Psychological Therapies service. They may also receive medication and in extreme cases a  
14 period of in-patient hospital treatment.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 (Place Figure 1 here)  
27

### 28 **Proposed sample size**

29  
30  
31 In this feasibility trial no formal statistical testing of between group differences is planned.  
32 Sample size has been selected heuristically with the goal of i) demonstrating that participants  
33 can be recruited at a rate sufficient to run a full scale evaluation of SAFE at a later date; ii)  
34 demonstrating that it is possible to train therapists and deliver SAFE to patients within the  
35 study treatment settings, and iii) demonstrate that the data collection procedures are  
36 effective, and that the data collection is acceptable to the 36 families, and not overly  
37 burdensome.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Data analysis**

49  
50 Completed paper case report forms will be checked and signed by research staff before  
51 being sent to the Peninsula Clinical Trials Unit (CTU). Original case report form pages will  
52 be posted to the CTU at agreed time points for double-data entry on to a password-  
53 protected database, with copies retained at the study site. Forms will be tracked using a  
54 web-based trial management system. Data will be analysed and presented as is  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 appropriate for a feasibility study, in particular concentrating on descriptive analyses and  
5  
6 undertaking no formal comparisons between groups. Reporting will follow the principles of  
7  
8 the CONSORT Statement using the checklist and flowchart as recommended in the  
9  
10 CONSORT extension for Randomized Pilot and Feasibility [62]. The flowchart will provide  
11  
12 detail about the number of families approached, number eligible, number consenting,  
13  
14 number randomised, number receiving allocated intervention and number assessed for  
15  
16 outcome data at each time point. As appropriate, details will be given for individual  
17  
18 members of the family, for example, how many family members there are and how many  
19  
20 completed each questionnaire. Wherever possible, detailed reasons will be given for  
21  
22 exclusions, loss to follow-up, non-completion of outcome measures etc.

23  
24  
25 Numbers will also be provided by centre and group, to inform the logistics of recruiting nine  
26  
27 families prior to randomisation and following them up after randomisation. For those  
28  
29 randomised to the SAFE intervention, adherence will be reported according to the number  
30  
31 of group sessions attended and participation of individual family members at each of the  
32  
33 therapy sessions. Completeness of data will be reported for each outcome measure at each  
34  
35 relevant time point. Again this will be reported for individual family members as appropriate.  
36  
37  
38 For each outcome measure, the relevant scores will be calculated and presented  
39  
40 descriptively by trial arm. Where available, published guidelines will be used to process, score  
41  
42 and summarise the measures including, for example, the use of imputation in the event of  
43  
44 missing items on a questionnaire. Summary measures will be calculated as appropriate, for  
45  
46 example, means and standard deviations, medians and ranges, numbers and percentages  
47  
48 in categories. These measures will be presented both for baseline and for the final follow-up.  
49  
50 The only analysis contrasting the two groups will be an interval estimate in the form of a 95%  
51  
52 confidence interval for the primary outcome, so that the plausibility for the effect size used in  
53  
54 the sample size calculation for the full trial can be assessed. For this purpose the baseline  
55  
56 values will be used in an Analysis of Covariance, with acknowledgment that no effects are  
57  
58 included for group or therapist.  
59  
60

1  
2  
3  
4 Focus group interviews will be audio recorded and transcribed verbatim. Consequent  
5 qualitative data will be managed using proprietary computer assisted qualitative data analysis  
6 software, for example, Nvivo 10, and analysed thematically [63,64]. Rigour of analysis will  
7 include 'respondent validation', whereby participants are provided with a summary of their  
8 transcript and analysis so that they can assess whether the interpretations being made about  
9 the data, accurately represent them. In addition, a second qualitative researcher will conduct  
10 an independent analysis of a subset of half of the focus group transcripts. Researchers will  
11 then meet to discuss and agree the findings, which will then be presented to the Family  
12 Consultation Group for discussion.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

## 25 **Patient and Public Involvement**

26  
27 Families of children with autism initiated the development of this project by communicating  
28 their complex needs and dissatisfaction with current service provision through the Plymouth  
29 Autism Network. This Network was set up by the Chief Investigator in 2011 to bring  
30 clinicians, carers, academics and individuals with autism together to share ideas, research  
31 findings and experiences. We further explored the challenges facing families of children  
32 with autism by conducting in-depth interviews and surveying over 90 families regarding their  
33 needs and the treatment they received post-diagnosis. Less than 9% of families agreed that  
34 current treatment helped with the problems they face. Our survey revealed a strong need  
35 for interventions, which support the whole family.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 This pilot data led to the development of a research team within the Wellcome Research  
49 Hub at Plymouth University, which included a Family Consultation Group. Our Family  
50 Consultation Group worked with us to develop and refine the SAFE intervention prior to the  
51 current project. These families have also contributed to the creation of a recruitment and  
52 treatment plan, which will be manageable for families. They have offered advice about how  
53 it is best to communicate with families at the start of the study and as it progresses. In  
54 addition, the Family Consultation Group representative is a co-applicant on this  
55  
56  
57  
58  
59  
60



1  
2  
3 study.  
4  
5  
6  
7

8 Our Family Consultation Group will continue to be essential members of the team and work  
9 as an advisory group throughout the feasibility study and beyond. Formal structures are in  
10 place to ensure ongoing collaboration with the Family Consultation Group. Specifically, the  
11 representative for the Consultation Group is paid as a research assistant on the trial and is  
12 a co-applicant. She attends and actively contributes to monthly trial management group  
13 meetings, all training sessions and fortnightly research team meetings. The representative  
14 reports key issues and requests to and from the wider group. Where necessary, additional  
15 meetings are held between the family Consultation Group as a whole and other research  
16 staff. In these instances travel and subsistence costs are available in line with National  
17 Health Service England guidelines on working with our patient and public voice partners  
18 [65].  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 We see our Family Consultation Group as experts in their own lives and the lives of families  
32 with similar challenges. For this reason we feel our role is to work with them in a supportive  
33 manner as collaborators. Their contribution is valuable in the same way as other experts on  
34 the team and we aim to facilitate one another. As stated above, the Family Consultation  
35 Group have been active in contributing to the research plan. Their input is of particular  
36 value in developing recruitment procedures, designing participant information packs and  
37 providing information about potential barriers to retention. We have also worked with them  
38 to prepare and deliver a training programme for research staff and therapists. With their  
39 help we have trained recruited staff work in a sensitive and informed manner with  
40 participants. We also value their input in interpreting and reporting data; in particular  
41 commenting on possible ways to overcome challenges for the main RCT.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Our families can help by identifying local networks and sharing their experience with new  
56 groups. Our Family Consultation Group are proactive campaigners for change and have  
57 extensive knowledge of existing bodies such as the National Autistic Society. They can also  
58  
59  
60

1  
2  
3 provide a family-centred perspective on research outcomes. They are, therefore, well-  
4 placed to collaborate with us in planning next steps and disseminating findings at local and  
5 national levels.  
6  
7  
8  
9  
10  
11  
12

## 13 ETHICS AND DISSEMINATION

### 16 Risks and safety

17  
18 Families of children with autism are a potentially vulnerable group. The risks associated  
19 with participating in this study are however, considered minimal, with no adverse events  
20 anticipated in any participant. For those in the intervention group, there is a slight chance  
21 that the SAFE family therapy sessions could lead to an initial increase in family  
22 disagreements as family members learn how to change the way they solve problems and  
23 talk with one another. However, the purpose of the intervention is ultimately to equip  
24 families with skills to handle these difficulties by learning how to change the way they solve  
25 problems and improve their communication, and the SAFE family therapists will be  
26 available to provide support and will be trained to handle any emerging problems. Should  
27 any issues arise the SAFE family therapists will have access to two consultant clinical  
28 psychologists to provide further support and advice.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 During the trial the children with autism will remain in the care of the Child Development  
44 Centre or the Autism Spectrum Disorder Assessment Team and will have access to usual  
45 care should any unforeseen circumstances arise. Other members of the family will also  
46 continue to be able to seek care and advice from the GP or any other specialist services  
47 they are concurrently involved with.  
48  
49  
50  
51  
52  
53

### 54 Monitoring adverse events

55 The research team have mechanisms in place to report serious adverse events (SAE)  
56 related to mental health. Serious Adverse Events related to mental health may be  
57  
58  
59  
60

1  
2  
3  
4 volunteered by the participant or discovered by the therapists, research assistants or other  
5 member of the research team during the SAFE family therapy sessions, or as a result of  
6 direct reporting (e.g. by telephone) by a family member, independent clinician or other  
7 informant. Serious adverse events will be recorded from the time of consent until the date  
8 the participant completes the follow-up or withdraws from the study.  
9  
10  
11  
12

13  
14 If the CI considers that the SAE is not, or is unlikely to be, associated with the trial, the CTU  
15 will obtain a second assessment of causality from an independent assessor. Any SAE  
16 which in the opinion of either adjudicator is possibly related to the trial will be reported to the  
17 Research Ethics Committee within 15 days of the local research team having become  
18 aware of the event. All SAEs will be followed until either stabilised if chronic conditions or  
19 resolved.  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **Dissemination**

30  
31 If the feasibility study meets progression criteria an important part of our dissemination plan  
32 is to raise awareness of the need for a larger multi-centre trial. We will, therefore, offer  
33 targeted summaries of our findings and presentations to policy makers. The findings will  
34 also be broadly disseminated, but in a manner appropriate to a feasibility study. We plan  
35 national conference presentations and published papers to inform clinicians, academics  
36 and therapists about the possible benefits of SAFE and generate interest in the future trial.  
37 We will make use of our existing connections including the Association for Family Therapy,  
38 the National Autistic Society and the Institute of Family Therapy to reach relevant  
39 audiences. Our qualitative findings will also be published with detailed accounts of the  
40 families' reactions to SAFE and their views on its effectiveness. We will also provide forums  
41 for participating families to share their own experiences of the intervention with wider  
42 audiences through existing networks, groups and events across the UK.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 Our Family Consultation Group will be integral to our dissemination plan. Their involvement  
58 will include presenting their experiences as delegates at national and international  
59  
60

1  
2  
3  
4 conferences, being active co-authors on published papers, leading the organising  
5  
6 committee for a local event sharing findings with families, key local stakeholders, clinicians  
7  
8 and other interested partners; and liaising with other bodies to raise awareness of the study  
9  
10 findings including Autistica, The National Autistic Society and the Brandon Trust.  
11  
12  
13

### 14 **Informing potential participants of possible benefits and known risks**

15  
16  
17 The participant information sheets and leaflets will provide potential participants with  
18  
19 information about the possible benefits and risks of taking part in the trial. For example, the  
20  
21 participants will be informed that a potential risk of receiving the SAFE therapy is that the  
22  
23 sessions may evoke difficult emotions and feelings this could lead to family disagreement  
24  
25 as they move towards change. The families will also be informed that benefits of the trial  
26  
27 include the possibility of improved coping skills when faced with challenges and contribution  
28  
29 to finding out if SAFE can progress to a national trial. Participants will be given the  
30  
31 opportunity to discuss risks and benefits with a member of the research team prior to  
32  
33 consenting to participate.  
34  
35  
36  
37

### 38 **Obtaining Informed consent from participants**

39  
40  
41 All participants will receive a leaflet and information sheet prior to consent. There are two  
42  
43 versions of the information sheet, one for adults and one for children. In the leaflet parents  
44  
45 are encouraged to explain the trial to their younger children and some guidance for doing  
46  
47 this is provided. The information sheet states that the participants have the right to withdraw  
48  
49 at any point during the trial and that data collected from them will be confidential. All  
50  
51 participants will have a home-visit prior to consent from a member of the research team and  
52  
53 will be able to ask questions or go through the information verbally. Participants will have  
54  
55 the process of the study explained to them including the estimated time they will have to  
56  
57 wait prior to randomisation and starting the intervention if allocated to that arm.  
58  
59  
60

## **Data protection/confidentiality**

Participants will be given a unique identification number. The data will be pseudo-anonymised in the sense that there will be an identification number on the documentation but otherwise no means of identifying the individual to which the data relates. The research team will ensure that participants' pseudo-anonymity is maintained on all documents. Data will be collected and stored in accordance with the current legal and regulatory documentation. Electronic study records will be stored in a SQL server database, stored on a restricted access, secure server maintained by Plymouth University. Data will be entered into the database via a bespoke web-based data entry system encrypted using SSL. Access to electronic data will be permission based, and at the discretion of the clinical trials unit data management team.

Anonymised paper-based study data will be stored in locked filing cabinets. Copies of study data retained at the lead study site will be securely stored for the duration of the study prior to archiving. Video data will be transported via encrypted memory sticks and will be transferred to a password-protected computer. The clinical trials unit data team will have access to study data, including identifiable data. Other members of the study team and the trials unit will have restricted access to pseudo-anonymised study data. Access will be granted to the Sponsor and host institution on request, to permit study-related monitoring, audits and inspections.

## **Research governance and the conduct of the trial**

The trial will be conducted to protect the human rights and dignity of the participant as reflected in the Helsinki Declaration. An important factor in protecting the participants is ongoing consultation with the SAFE Family Consultation Group. A representative of this group is a member of the research team and is involved in decision-making processes. The research team including the family consultation group are proactive in minimising

1  
2  
3 discomfort and risk for participants, respecting their wishes over science and society,  
4 respecting the right to withdraw and the need for families to have access to all relevant  
5 information.  
6  
7  
8  
9

10 The Chief Investigator will be responsible for the overall conduct of the study, keeping it to  
11 schedule and within budget. Working closely with the CTU she will be the focal contact for  
12 enquiries from both sites. The CTU will manage the study, liaise with sites, monitor  
13 recruitment, work with the Sponsor and report to Trial Management Group (TMG) meetings.  
14 The TMG will meet regularly throughout the feasibility study. A Trial Steering Committee  
15 (TSC) will have an overarching monitoring responsibility. The TSC is expected to meet  
16 three times during the study, but will be additionally convened at the chairman or Chief  
17 Investigator's request.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Dissemination plans**

30  
31  
32 If the feasibility study demonstrates successful recruitment, data collection and an ability to  
33 deliver the intervention, an important part the dissemination plan is to raise awareness of  
34 the need for a larger multi-centre trial. Targeted summaries of the findings and  
35 presentations will be disseminated to policy makers. The findings will also be broadly  
36 disseminated, but in a manner appropriate to a feasibility study. National conference  
37 presentations and published papers will be prepared to inform clinicians, academics and  
38 therapists about our feasibility results and generate interest in the future trial. Existing  
39 connections including the Association for Family Therapy, the National Autistic Society and  
40 the Institute of Family Therapy will be utilised to reach relevant audiences. The qualitative  
41 findings will also be published with detailed accounts of the families' reactions to SAFE and  
42 their views on its usefulness. A summary of study results in plain English will be available  
43 on the Peninsula Clinical Trials website.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Clinical trials authorisation and ethical approval

Clinical trials authorisation is not required. The study has appropriate Research Ethics Committee (REC) approval from the South West-Exeter Research Ethics Committee (Ref: 17/SW/0192) and approval from the Health Research Authority (HRA). The trial will be conducted in accordance with the protocol, the principles of the Declaration of Helsinki and ICH GCP. Any amendments of the protocol will be submitted to the Sponsor, HRA and REC for approval.

## Trial sponsorship

The trial is sponsored by University Hospitals Plymouth NHS Trust.

## Trial Steering Committee

The Trial Steering Committee will include an independent chair and at two other independent members, along with the lead investigator and the other study collaborators including a parent representative. They will meet once a year.

## REFERENCES

1. National Autistic Society, 'Autism Facts and History', accessed 22 March 2018
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, Washington, DC 2013.
3. Sasson NJ, Lam KSL, Parlier M, et al. Autism and the broad autism phenotype: familial patterns and intergenerational transmission. *J Neurodev Disord* 2013; 5:11-18.
4. Dykens EM, Fisher MH, Taylor JL, et al. Reducing Distress in Mothers of Children with Autism and Other Disabilities: A Randomized Trial. *Pediatrics* 2014; 2013-3164.

- 1  
2  
3  
4 5. Hallett V, Ronald A, Colvert, E, et al. Exploring anxiety symptoms in a large-scale twin  
5  
6 study of children with autism spectrum disorders, their co-twins and controls. *Journal*  
7  
8 *of Child Psychology and Psychiatry* 2013;54:1176-1185.  
9
- 10  
11 6. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with  
12  
13 autism compared to young people with intellectual disability. *J Autism Dev Disord*  
14  
15 2006;36: 863-870.  
16
- 17  
18 7. Kim JA, Szatmari P, Bryson SE, et al. The prevalence of anxiety and mood problems  
19  
20 among children with autism and Asperger syndrome. *Autism* 2000; 4:117-132.  
21  
22
- 23  
24 8. Howlin P. Interventions for people with autism: recent advances. *Adv Psychiatr Treat*  
25  
26 1997;3: 94-102.  
27
- 28  
29 9. Mazefsky CA, Folstein SE, Lainhart JE. Overrepresentation of Mood and Anxiety  
30  
31 Disorders in Adults with Autism and Their First Degree Relatives: What Does it  
32  
33 Mean? *Autism Res* 2008;1:193-197.  
34
- 35  
36 10. Daniels JL, Forssen U, Hultman M, et al. Parental Psychiatric Disorders Associated  
37  
38 With Autism Spectrum Disorders in the Offspring. *Pediatrics* 2008;121:1357-1162.  
39
- 40  
41 11. Siklos S, Kerns KA. Assessing Need for Social Support in Parents of Children with  
42  
43 Autism and Down Syndrome. *J Autism Dev Disord* 2008;36:921-933.  
44
- 45  
46 12. Markoulakis R, Fletcher P, Bryden P. Seeing the glass half full: benefits to the lived  
47  
48 experiences of female primary caregivers of children with autism. *Clin Nurse Spec.*  
49  
50 2012;26(1):48–56.  
51
- 52  
53 13. Potter CA. 'I accept my son for who he is – he has incredible character and personality':  
54  
55 fathers' positive experiences of parenting children with autism. *Disabil Soc,*  
56  
57 2016;31(7):948-965.  
58  
59  
60



- 1  
2  
3  
4 14. Myers BJ, Mackintosh VH, Goin-Kochel RP. "My greatest joy and my greatest heart  
5 ache:" Parents' own words on how having a child in the autism spectrum has  
6 affected their lives and their families' lives. *Res Autism Spectr Disord*. 2009;3(3):670-  
7 684.  
8  
9
- 10  
11  
12 15. Zhang W, Yan TT, Barriball KL, While AE, Liu XH. Post-traumatic growth in mothers of  
13 children with autism: a phenomenological study. *Autism*. 2015;19(1):29-37.  
14  
15
- 16  
17  
18 16. Altieri MJ, von Kluge S. Searching for acceptance: challenges encountered while  
19 raising a child with autism. *J Intellect Dev Disabil*. 2009;34(2):142-152.  
20  
21
- 22  
23  
24 17. McCrone P, Dhanasiri S, Patel A, et al. The cost of mental health care in England to  
25 2026. Executive Summary, London: The King's Fund. 2008  
26  
27
- 28  
29 18. Buescher AVS, Cidav Z, Knapp M, et al. Costs of Autism Spectrum Disorders in the  
30 United Kingdom and the United States. *JAMA Pediatr* 2014;e1-e8.  
31  
32
- 33  
34 19. Osborne LA, McHugh L, Saunders J, et al. Parenting Stress Reduces the Effectiveness  
35 of Early Teaching Interventions for Autistic Spectrum Disorders. *J Autism Dev*  
36 *Disord* 2008;38:1092-1103.  
37  
38
- 39  
40  
41 20. Pisula E. Parenting Stress in Mothers and Fathers of Children with Autism Spectrum  
42 Disorders, A Comprehensive Book on Autism Spectrum Disorders, Dr. Mohammad-  
43 Reza Mohammadi (Ed.) 2011. Available from: [http://www.intechopen.com/books/a-](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
44 [comprehensive-](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
45 [bookon-](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
46 [autism-spectrum-disorders/parenting-stress-in-mothers-](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
47 [and-fathers-of-children-with-autismspectrum-disorders](http://www.intechopen.com/books/a-comprehensive-bookon-autism-spectrum-disorders/parenting-stress-in-mothers-and-fathers-of-children-with-autismspectrum-disorders)  
48  
49  
50
- 51  
52  
53 21. Nikmat AW, Ahmad M, Oon NL, et al. Stress and psychological wellbeing among  
54 parents of children with autism spectrum disorder. *ASEAN Journal of Psychiatry*  
55 2008;9:65-72.  
56  
57  
58  
59  
60

- 1  
2  
3  
4 22. Bolton PF, Pickles A, Murphy M, et al. Autism, affective and other psychiatric disorders:  
5 patterns of familial aggregation. *Psychological Medicine* 1998;28: 385-395.  
6  
7  
8  
9 23. Demir T, Dogangun B, Karacetin G, et al. Psychiatric Disorders and Symptoms in  
10 Mothers of Children with Autistic Disorder. *Neurol Psychiatry Brain Res* 2008;15:1-5.  
11  
12  
13  
14 24. Piven J, Palmer P. Psychiatric disorder and the broad autism phenotype: evidence from  
15 a family study of multiple-incidence autism families. *Am J Psychiatry* 1999;156:557-  
16 563.  
17  
18  
19  
20  
21 25. Roberts AL, Koenen KC, Lyall K, Ascherio A, Weisskopf MG. Women's posttraumatic  
22 stress symptoms and autism spectrum disorder in their children. *Res Autism Spectr*  
23 *Disord* 2014;8(6):608-616.  
24  
25  
26  
27  
28 26. Roberts AL, Lyall K, Rich-Edwards JW, Ascherio A, Weisskopf MG. Maternal exposure  
29 to intimate partner abuse before birth is associated with autism spectrum disorder in  
30 offspring. *Autism* 2016;20(1):26-36.  
31  
32  
33  
34  
35 27. Konstantareas MK. Autistic, learning disabled and delayed children's impact on their  
36 parents. *Can J Behav Sci* 1991;23:358-375.  
37  
38  
39  
40  
41 28. Murphy M, Bolton PF, Pickles A, et al. Personality traits of the relatives of autistic  
42 probands. *Psychol Med* 2000;30:1411-1424.  
43  
44  
45  
46 29. Blackledge JT, Hayes SC. Using Acceptance and Commitment Training in the Support  
47 of Parents of Children Diagnosed with Autism. *Child & Family Behavior Therapy*,  
48 2006;28:1-18.  
49  
50  
51  
52  
53 30. NICE guidelines [CG170] [https://www.nice.org.uk/guidance/cg170/chapter/patient-](https://www.nice.org.uk/guidance/cg170/chapter/patient-centred-care)  
54 [centred-care](https://www.nice.org.uk/guidance/cg170/chapter/patient-centred-care)  
55  
56  
57  
58 31. NICE guidelines [CG128] <https://www.nice.org.uk/guidance/cg128>  
59  
60

- 1  
2  
3  
4 32. Munroe E. The Munroe Review of Child protection: Final report, Dept. of Education, HM  
5 Stationary Office, UK 2011.  
6  
7  
8  
9 33. Goodman S, Trowler I. Social work re-claimed: Innovative frameworks for child and  
10 social work Practice. London: Jessica Kingsley 2012.  
11  
12  
13  
14 34. NHS England. Future in Mind: promoting, protecting and improving our children and  
15 young people's mental health and wellbeing. Dept of Health Publication Gateway  
16 Ref. No 02939, 2015.  
17  
18  
19  
20  
21 35. IAPT | CYP IAPT Children and Young People's Project. (n.d.). Retrieved January 5,  
22 2015, from <http://www.iapt.nhs.uk/cyp-iapt/>  
23  
24  
25  
26 36. Bromley J, Hare DJ, Davison K. et al. Mothers supporting children with autistic  
27 spectrum disorders: Social support, mental health status and satisfaction with  
28 services. *Autism* 2004;8:409-423.  
29  
30  
31  
32  
33 37. Stratton P. Report On The Evidence Base Of Systemic Family Therapy. *Association for*  
34 *Family Therapy* 2005.  
35  
36  
37  
38 38. Dallos R, Draper R. (4th Edn) An Introduction to Family Therapy. Maidenhead: Open  
39 Univ. Press/McGraw Hill 2015.  
40  
41  
42  
43  
44 39. Monteiro M. Family Therapy and the Autism Spectrum: Autism Conversations in  
45 Narrative Practice. London: Routledge 2016.  
46  
47  
48  
49 40. Estrada AU, Pinsof WF. The effectiveness of family therapies for selected behavioural  
50 disorders of childhood. *J Marital Fam Ther* 1995;21: 403-424.  
51  
52  
53  
54 41. Pellicano E, Dinsmore A, Charman T. What should autism research focus upon?  
55 Community views and priorities from the United Kingdom. *Autism, Special Issue*  
56 *Article* 2014:1-15.  
57  
58  
59  
60

- 1  
2  
3  
4 42. Wallace S, Parr J, Hardy, A. One in a hundred: Putting families at the heart of autism  
5 research. London: Autistica 2013.  
6  
7  
8  
9 43. Wechsler D. WISC-V: Technical and Interpretive Manual. NCS Pearson, Incorporated;  
10 2014.  
11  
12  
13  
14 44. Eliot CD, Smith P. British Ability Scales , BAS3. London, United Kingdom: GL  
15 Assessment. 2011.  
16  
17  
18  
19 45. Stratton P, Bland J, Janes E, et al. Developing an indicator of family function and a  
20 practicable outcome measure for systemic family and couple therapy: the SCORE.  
21 *Journal of Family Therapy* 2010;32:232-258.  
22  
23  
24  
25  
26 46. Stratton P, Lask J, Bland J, Nowotny E, Evans C, Singh R, Janes E, Peppiatt A.  
27 Detecting therapeutic improvement early in therapy: validation of the SCORE-15  
28 index of family functioning and change. *J Fam Ther* 2014;36:3-19.  
29  
30  
31  
32  
33 47. SHIFT Self-Harm Intervention, Family Therapy: a randomised controlled trial of family  
34 therapy vs. treatment as usual for young people seen after second or subsequent  
35 episodes of self harm. Protocol Grant Number: 470772 HTA Reference Number:  
36 07/33/01, 2015.  
37  
38  
39  
40  
41  
42 48. SCORE-15 [Internet ] Association for Family Therapy [www.aft.org.uk](http://www.aft.org.uk). [cited 2018 Sept  
43 17] Available from:  
44 [http://www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/SCORE%20info/SCORE-  
45 15%20102013.pdf](http://www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/SCORE%20info/SCORE-15%20102013.pdf)  
46  
47  
48  
49  
50 49. Kroenke K, Spitzer RL, Williams JBW, Lowe B. The Patient Health Questionnaire  
51 Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp  
52 Psychiatry* 2010;32:345-359.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 50. Spitzer R L, Kroenke K, Williams JBW. The Patient Health Questionnaire Primary Care  
5 Study Group. Validation and utility of a self-report version of PRIME-MD: the PHQ  
6 Primary Care Study. *JAMA*, 282, 1999:1737-1744.  
7  
8  
9  
10  
11 51. Blazey L. Coding of Attachment-Related Parenting for use with children with Autism  
12 (CARP-A) [dissertation]. Manchester: Manchester University, 2007.  
13  
14  
15  
16 52. Holt CE. Child-caregiver Play and Attachment in Pre-school Autism: A Longitudinal  
17 Investigation [thesis]. Manchester: University of Manchester, 2011.  
18  
19  
20 53. Moss E, Bureau J, Cyr C, et al. Correlates of attachment at age 3 Construct validity of  
21 the Preschool Attachment Classification System. *Dev. Psychol* 2004;40:323-334.  
22  
23  
24  
25 54. Achenbach TM, Rescorla LA. Manual for the ASEBA School-Age Forms and Profiles:  
26 Child Behaviour Checklist for Ages 6-18. Burlington, VT: University of Vermont,  
27 Research Center for Children, Youth, & Families. 2001.  
28  
29  
30  
31  
32 55. Fonagy P, Luyten P, Moulton-Perkins A, et al. Development and validation of a self-  
33 report measure of mentalizing: The Reflective Functioning Questionnaire. *PLOS*  
34 *ONE*. 2016;11(7):e0158678.  
35  
36  
37  
38  
39 56. Solomon J, George C. (Eds.) *Disorganised Attachment and Caregiving*. Guilford: New  
40 York; 2011.  
41  
42  
43  
44 57. Huth-Bocks AC, Guyon-Harris K, Calvert M, Scott S, Ahlfs-Dunn S. The Caregiving  
45 Helplessness Questionnaire: Evidence for validity and utility with mothers of infants.  
46 *Infant Ment Health J*. 2016;37:208-221.  
47  
48  
49  
50  
51 57. Ogletree BT, Morrow-Odom KL, Wrestling D. Understanding the brain-behaviour  
52 relationship in persons with ASD: Implications for PECS as a treatment choice. *Dev*  
53 *Neurorehabil* 2015;18(2): 88-96.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 58. Buron KD, Wolfberg P. Learners on the autism spectrum: Preparing highly qualified  
5  
6 educators (pp. 114–137). AAPC Publishing: Shawnee; 2008.  
7  
8  
9 59. Grandin T, Scariano MM. (1986). *Emergence: Labeled autistic*. New York, NY: Warner  
10 Books 1986.  
11  
12  
13  
14 60. Slade A, Aber JL, Bresgi I, Berger B, Kaplan M. The parent development interview,  
15 revised. Unpublished protocol. The City University of New York 2004.  
16  
17  
18  
19 61. Dallos R, Draper R. *An introduction to family therapy: Systemic theory and practice*.  
20 McGraw-Hill Education (UK); 2015.  
21  
22  
23  
24 62. CONSORT extension for Randomized Pilot and Feasibility Trials ([http://www.consort-](http://www.consort-statement.org/randomised-pilot-and-feasibilitytrials)  
25 [statement.org/randomised-pilot-and-feasibilitytrials](http://www.consort-statement.org/randomised-pilot-and-feasibilitytrials)).  
26  
27  
28  
29 63. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*.  
30 2006;3:77-101.  
31  
32  
33 64. Green J, Thorogood N. *Qualitative Health Methods for health Research*. London: Sage  
34 Publications; 2004.  
35  
36  
37  
38 65. NHS ENGLAND. Working with our Patient and Public Voice (PPV) Partners –  
39 Reimbursing expenses and paying involvement payments. 2017.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **AUTHORS' CONTRIBUTIONS:** RM, JV and HH were responsible for the overall  
51 development of the protocol. RM, HH, RD, CM, PE, AB, TV and the Family Consultation  
52 Group were involved in the conception and production of the study and the development of  
53 the initial protocol. PE and AB provided methodological expertise and advice on quantitative  
54 analysis PE provided statistical expertise. RD was the lead researcher, with the support of  
55  
56  
57  
58  
59  
60

1  
2  
3 JS, on design of the intervention and the qualitative component. TV, with the support of the  
4 Family Consultation Group, and CM advised on design and ethics, particularly from the  
5 participant perspective. All authors made substantial contributions to drafting, revision and  
6 approval of the document.  
7  
8  
9  
10

11  
12 **ACKNOWLEDGEMENTS:** The Authors would like to thank the SAFE Family Consultation  
13 Group for their ongoing input and expertise. They would also like to thank James Cook,  
14 Mary Hosken, Dr Ben Whalley, Dr Antonieta Medina-Lara and Professor Julian Archer for  
15 their help in developing and conducting this study. The authors would also like to give  
16 special recognition to the dedication, hard-work and sensitivity of Helen Hancocks, the  
17 SAFE trial manager for the Peninsula Clinical Trials Unit.  
18  
19  
20  
21  
22  
23

24  
25  
26 **FUNDING STATEMENT:** This work was supported by the National Institute for Health  
27 Research (NIHR) grant number: PB-PG-0815-20058  
28  
29


30  
31 **COMPETING INTERESTS STATEMENT:** Contributors are co-applicants or employed  
32 research staff on the SAFE project, which receives funds from both NIHR and Autistica.  
33 Professor Rudi Dallos holds joint Intellectual Property rights for the SAFE intervention with  
34 The University of Plymouth. No other issues were raised with regard to competing interests.  
35  
36  
37  
38

39  
40 **PROVENANCE AND PEER REVIEW:** Not commissioned; externally peer reviewed.  
41  
42

43  
44 **DATA SHARING STATEMENT:** Further details of the study protocol can be requested from  
45 the corresponding author.  
46  
47  
48  
49

50  
51  
52  
53 **Caption for Figure 1:**  
54  
55  
56  
57

58  
59 **Figure 1. Study Schema**  
60







SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Front page
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Front page
	2b	All items from the World Health Organization Trial Registration Data Set	Front page, 6, 9
Protocol version	3	Date and version identifier	Front page
Funding	4	Sources and types of financial, material, and other support	34
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	6
	5b	Name and contact information for the trial sponsor	6
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	5
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	30 - 32

## Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	10 -11
	6b	Explanation for choice of comparators	29 - 30
Objectives	7	Specific objectives or hypotheses	11 - 12
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	12

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	16
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	16
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	21 - 22
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	21
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	21, 30
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	22
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14 - 15
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	19

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations 29 - 30

Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 20

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 29 - 30

Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 19 - 20

Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 20

Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 20 - 21

17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial 20 - 21

**Methods: Data collection, management, and analysis**

Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 27 - 29

18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols 24 - 25

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	28
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	29 - 30
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	25 - 26
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	29 - 30
13				
14				
15	<b>Methods: Monitoring</b>			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	31 - TSC performing DMC role.
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	33
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	26 - 27
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	30 - 31
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	32 - 33
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	32
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	18
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	23
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	28 - 29
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	29
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	33
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	33 - 34
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40